<?xml version="1.0" encoding="UTF-8"?><rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0" xmlns:cc="http://cyber.law.harvard.edu/rss/creativeCommonsRssModule.html">
    <channel>
        <title><![CDATA[Stories by Guidechem on Medium]]></title>
        <description><![CDATA[Stories by Guidechem on Medium]]></description>
        <link>https://medium.com/@guidechem2009?source=rss-3d079ec9b13d------2</link>
        <image>
            <url>https://cdn-images-1.medium.com/fit/c/150/150/1*qSJKw5L9p_aKYF2y6rcWCw.png</url>
            <title>Stories by Guidechem on Medium</title>
            <link>https://medium.com/@guidechem2009?source=rss-3d079ec9b13d------2</link>
        </image>
        <generator>Medium</generator>
        <lastBuildDate>Sun, 22 Nov 2026 22:21:09 GMT</lastBuildDate>
        <atom:link href="https://medium.com/@guidechem2009/feed" rel="self" type="application/rss+xml"/>
        <webMaster><![CDATA[yourfriends@medium.com]]></webMaster>
        <atom:link href="http://medium.superfeedr.com/" rel="hub"/>
        <item>
            <title><![CDATA[What Are Pharmaceuticals? Types, Manufacturing, and How the Industry Sources Its Raw Materials]]></title>
            <link>https://guidechem2009.medium.com/what-are-pharmaceuticals-types-manufacturing-and-how-the-industry-sources-its-raw-materials-d403f8829409?source=rss-3d079ec9b13d------2</link>
            <guid isPermaLink="false">https://medium.com/p/d403f8829409</guid>
            <category><![CDATA[business]]></category>
            <category><![CDATA[sales]]></category>
            <category><![CDATA[pharmaceutical]]></category>
            <category><![CDATA[b2b]]></category>
            <dc:creator><![CDATA[Guidechem]]></dc:creator>
            <pubDate>Wed, 18 Nov 2026 02:08:40 GMT</pubDate>
            <atom:updated>2026-11-18T02:08:40.256Z</atom:updated>
            <content:encoded><![CDATA[<blockquote><strong>A pharmaceutical is a drug — a substance formulated to diagnose, treat, cure, or prevent disease.</strong> Every finished medicine is built from three ingredient classes: the <strong>active pharmaceutical ingredient (API)</strong> that produces the therapeutic effect, <strong>excipients</strong> that give the dosage form its structure and stability, and, upstream in the supply chain, <strong>pharmaceutical intermediates</strong> used to synthesize the API itself. Examples of well-known APIs include paracetamol (acetaminophen, CAS 103–90–2), ibuprofen (CAS 15687–27–1), and aspirin (CAS 50–78–2).</blockquote><h4><strong>Key points</strong></h4><ul><li>The global pharmaceutical market is valued at roughly <strong>USD 1.5 trillion</strong>, spanning originator drugs, generics, biologics, and over-the-counter medicines.</li><li>A medicine is never one chemical: it is an API plus a defined excipient blend, manufactured under GMP with batch-level documentation (COA, and for APIs, a Drug Master File).</li><li>Most APIs originate in <strong>China and India</strong>, while high-value biologics concentrate in the United States and Europe — sourcing decisions always carry this geography. Where are most pharmaceuticals made? The answer to that single question often decides landed cost and lead time before a quote is even requested.</li><li>Buyers of drug substances, intermediates, and excipients can search <strong>2,232 suppliers and 55,000+ listed pharmaceutical products</strong> by CAS number on GuideChem.</li></ul><h3>What Does “Pharmaceutical” Mean?</h3><p><strong>What does pharmaceutical mean?</strong> The word — spelled p-h-a-r-m-a-c-e-u-t-i-c-a-l — functions two ways. As a noun, pharmaceuticals are medicinal products — tablets, capsules, injections, syrups, creams, and infusions sold by prescription or over the counter. As an adjective, it describes anything connected with the preparation, testing, and sale of those products: a pharmaceutical company, a pharmaceutical intermediate, the pharmaceutical industry, or the pharmaceutical supply chain. Both uses trace to <em>pharmakon</em>, the Greek term for a drug or remedy, while <em>pharmaceutics</em> names the underlying science of formulation — how an API becomes a stable, deliverable medicine.</p><h3>What Are Pharmaceuticals Made Of? Three Ingredient Classes</h3><p>Every dosage form decomposes into the same three layers, and each layer is a purchasable chemical category:</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/820/1*M0Ye5iG6QVDa-iDSh0fVnw.png" /></figure><p>A common confusion: “pharmaceutical drugs” and “medication” both refer to the finished product, while the raw-material trade is conducted one level below — by CAS number, grade, and documentation package rather than by brand name.</p><h3>How Are Pharmaceuticals Made?</h3><p>Manufacturing runs through four stages, each with its own buyer-relevant checkpoints:</p><ol><li><strong>Discovery and development.</strong> A candidate molecule is identified, optimized, and proven safe and effective through preclinical and clinical testing. Originator development typically takes 10–15 years.</li><li><strong>API production.</strong> Small-molecule drug substances are made by multi-step organic synthesis or fermentation; biologics are grown in cell cultures. API plants run under GMP with full batch records.</li><li><strong>Formulation.</strong> The API is blended with excipients and converted into a dosage form — direct compression for tablets, lyophilization or aseptic filling for injectables.</li><li><strong>Quality control and release.</strong> Each batch is assayed for identity, potency, dissolution, impurity profile, and microbial limits before a certificate of analysis clears it for sale.</li></ol><h3>What Is a Pharmaceutical Company? What Do Pharmaceutical Companies Do?</h3><p>A pharmaceutical company researches, develops, manufactures, and markets medicines. In practice the industry splits into roles: <strong>originator (brand) companies</strong> that fund discovery and hold patents; <strong>generic companies</strong> that re-create off-patent drugs once exclusivity expires; <strong>CDMOs</strong> that manufacture on behalf of others; and the upstream <strong>API and intermediate producers</strong> that supply the drug substances. One finished product can pass through three or four companies’ hands before reaching a pharmacy, which is why supplier qualification is a regulatory requirement, not a formality. Across the globe there are tens of thousands of licensed manufacturers — how many pharmaceutical companies exist depends on whether one counts registered drug establishments, generic producers, or brand originators.</p><h3>What Is the Pharmaceutical Industry and How Big Is It?</h3><p>The pharmaceutical industry is the sector that develops, produces, and distributes medicines; to the question “what industry is pharmaceuticals,” the answer is healthcare manufacturing, closely linked to biotechnology and fine chemicals. How big is the pharmaceutical industry? Annual global medicine spending measures in the region of <strong>USD 1.5 trillion</strong> — what the pharmaceutical industry is worth makes it one of the largest regulated markets on earth. The largest companies — Johnson &amp; Johnson, Pfizer, Merck, Eli Lilly, AstraZeneca, and Roche — each generate tens of billions of dollars in pharmaceutical sales a year, with the top position rotating among them. Thousands of licensed manufacturers operate worldwide; in the United States alone, regulators maintain registration records for well over ten thousand drug establishments, from originators to contract packagers.</p><h3>Where Are Pharmaceuticals Manufactured? Understanding the Supply Chain</h3><p>The pharmaceutical supply chain — from starting materials to the medicine in a patient’s hand — runs in one direction: starting materials → intermediates → API → finished formulation → packaging → distribution, with regulatory filings layered onto every step. Asking “what is the pharmaceutical supply chain” is asking how a molecule crosses borders four or five times before it becomes a box on a shelf, and manufacturing is geographically specialized along that chain:</p><ul><li><strong>China</strong> is the world’s largest exporter of active pharmaceutical ingredients and key starting materials, with deep capacity in fermentation-derived APIs (penicillins, vitamins) and chemical synthesis.</li><li><strong>India</strong> dominates finished generic dosage forms — the “pharmacy of the world” label reflects its share of global generic supply and its large base of US FDA-inspected plants.</li><li><strong>The United States and Europe</strong> concentrate originator drugs, biologics, and high-value specialty formulations where cold-chain and regulatory infrastructure matter most.</li></ul><p>Where are most pharmaceuticals manufactured, then, and where are pharmaceutical drugs made for your specific molecule? Between them, China and India now supply the majority of global API tonnage and finished generic doses — which is why an API price is inseparable from its origin’s duty treatment, inspection history, and logistics. Multi-source strategies (typically one Asian and one Western or Eastern-European qualified supplier per critical molecule) became standard practice after recent supply shocks exposed single-source dependence.</p><h3>How to Open a Pharmaceutical Company: Sourcing Comes First</h3><p>New entrants often plan regulatory and marketing steps while underestimating the supply side. A viable launch sequence looks like this: choose a product portfolio (generic tablets, nutraceuticals, or licensed in-licensed formulations); qualify API and excipient suppliers who already hold the documentation your target market requires — Drug Master Files, GMP certificates, stability data, and batch COAs; secure a manufacturer or CMO with registered lines; then build dossiers for registration. Because qualified inputs determine dossier feasibility, serious founders shortlist their ingredient suppliers before they finalize their company structure.</p><h3>Sourcing APIs, Intermediates, and Excipients on GuideChem</h3><p>GuideChem indexes <a href="https://www.guidechem.com/product/listcas_catid-6039.html">pharmaceutical products</a> by CAS number, so the ingredient table above is a direct search path:</p><ul><li><strong>CAS-first discovery.</strong> Search paracetamol by 103–90–2 and compare every listed grade and pack size across producers rather than negotiating one cold email at a time.</li><li><strong>Supplier filtering.</strong> This category carries <strong>2,232 suppliers and more than 55,000 products</strong>; company profiles expose production scope, certifications, and trade history for shortlisting.</li><li><strong>Documentation up front.</strong> COA, MSDS, assay, and impurity profiles are requestable per listing — exactly the paperwork a qualified-materials review requires.</li><li><strong>One RFQ, parallel quotes.</strong> A single inquiry routes to matching suppliers and compresses sourcing cycles from weeks to days.</li></ul><h3>Frequently Asked Questions</h3><p><strong><em>What is a pharmaceutical product?</em></strong></p><p>A finished medicine in a specific dosage form — a tablet, injection, syrup, or cream — approved for sale with defined composition, strength, labeling, and storage conditions.</p><p><strong><em>What are pharmaceutical drugs?</em></strong></p><p>Medicinal substances used to treat, cure, or prevent disease. The phrase usually means finished medications; the industry distinguishes these from the APIs and intermediates they are manufactured from.</p><p><strong><em>What industry is pharmaceuticals?</em></strong></p><p>The healthcare sector, specifically the drug-manufacturing and drug-development sub-sector, closely linked to biotechnology and chemical manufacturing.</p><p><strong><em>What is the largest pharmaceutical company in the world?</em></strong></p><p>By pharmaceutical revenue the top position has rotated in recent years among Johnson &amp; Johnson, Eli Lilly, Merck, and Pfizer; by market capitalization the order shifts again. Ranking depends on which metric — revenue, R&amp;D spend, or prescription volume — is applied.</p><p><strong><em>What is a pharmaceutical intermediate?</em></strong></p><p>A chemical produced along the synthesis route between starting materials and the final API. Intermediates are traded as defined CAS compounds and are the first gate of quality and supply reliability in drug manufacturing.</p><h3>References</h3><ol><li>World Health Organization — Essential Medicines List and generic medicine guidance.</li><li>IQVIA Institute — Global Medicine Spending and Usage trends (2024–2026 editions).</li><li>U.S. Food and Drug Administration (FDA) — Drug establishment registration data and generic drug user-fee program reports.</li><li>European Medicines Agency (EMA) — Active substance and excipient guidance.</li><li>GuideChem Pharmaceutical category dataset — supplier and product counts, October 2026.</li></ol><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=d403f8829409" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[What Is Detergent? Its Ingredients, How It Works, and How to Buy Detergent Raw Materials in Bulk]]></title>
            <link>https://guidechem2009.medium.com/what-is-detergent-its-ingredients-how-it-works-and-how-to-buy-detergent-raw-materials-in-bulk-3938bc1dab2f?source=rss-3d079ec9b13d------2</link>
            <guid isPermaLink="false">https://medium.com/p/3938bc1dab2f</guid>
            <category><![CDATA[business]]></category>
            <category><![CDATA[detergent]]></category>
            <category><![CDATA[wholesale]]></category>
            <category><![CDATA[b2b]]></category>
            <dc:creator><![CDATA[Guidechem]]></dc:creator>
            <pubDate>Fri, 06 Nov 2026 06:29:30 GMT</pubDate>
            <atom:updated>2026-11-06T06:29:30.705Z</atom:updated>
            <content:encoded><![CDATA[<blockquote><strong>A detergent is a cleaning product built on surfactants — molecules that lower water’s surface tension so it can wet fabric, lift away oils, and hold soil suspended until the rinse.</strong> Laundry detergents combine an anionic surfactant backbone (such as LAS or SLES), builders that soften water, enzymes that digest protein and starch stains, bleach systems for whitening, and minor additives — each of them a defined chemical with its own CAS number that can be sourced directly from chemical manufacturers.</blockquote><h4>Key points</h4><ul><li>Detergent is chemistry, not a single substance: the active cleaning work comes from surfactants, and a good formula is a balanced system of 5–8 ingredient classes.</li><li>Detergent and soap are different chemistries — soaps are fatty-acid salts that fail in hard water; modern detergents were engineered precisely to fix that failure.</li><li>“Best detergent” questions all reduce to one practical trade-off: surfactant strength, enzyme package, and machine compatibility (standard vs. high-efficiency).</li><li>Wholesale buyers and private-label formulators buy the ingredient list itself — bulk surfactants, builders, and enzymes by CAS — from the <strong>320 suppliers and 1,374 products</strong> in <a href="https://www.guidechem.com/product/listcas_catid-7311.html">GuideChem’s Detergent category</a>.</li></ul><h3>What Is Detergent? What Does Laundry Detergent Do?</h3><p>The question of how to spell laundry detergent answers itself at any supermarket: two words, in that order, on every washing aisle. Detergents are substances that make cleaning more effective by changing how water behaves against soil and fabric. Their active agents, <strong>surfactants</strong>, are amphiphilic molecules: a water-loving (hydrophilic) head and an oil-loving (lipophilic) tail. In the wash, tails anchor into grease and oily stains while heads stay bonded to water; agitation then pulls the soil away from the fiber in tiny droplets — micelles — that the surfactants keep suspended until the rinse carries them out. Supporting ingredients handle the water itself: builders soften hardness ions, anti-redeposition agents keep loosened dirt from settling back, and enzymes attack specific stain chemistries. The result is cleaning that plain water, or even soap, cannot achieve in modern conditions.</p><h3>Is Detergent Soap? Two Different Chemistries</h3><p>No — and “is detergent soap” is the question that explains why laundry detergents exist at all. Soap is the salt of natural fatty acids (sodium stearate, sodium palmitate), made by saponifying fats. In hard water, soap carboxylates bind calcium and magnesium and drop out of solution as the sticky film known as soap scum, losing cleaning power exactly where water is hardest. Detergents — developed industrially from the 1940s onward — use sulfonate and sulfate chemistry (LAS, SLES) whose calcium salts stay soluble, so they keep working in any water. A third class, alkaline salt “builders” like washing soda, sits somewhere between: mineral cleaners with no surfactant content at all.</p><h3>What Is Laundry Detergent Made Of?</h3><p>What is in a laundry detergent? Every powder, liquid, and pod on the shelf shares the same ingredient architecture — and each component is a purchasable chemical:</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/701/1*QpfHt8NYZjxN7kiIMoqOfA.png" /></figure><p>Buyers often ask what is oxi in detergent — the label points to the bleach row above: sodium percarbonate (powders) or hydrogen peroxide (liquids), which release oxygen-based bleaching species in water. “Oxi” boosters sold as standalone products are almost pure percarbonate blended with carbonate builder.</p><h3>What Is the Best Laundry Detergent? A Buyer’s Decision Framework</h3><p>Whether the question is “what is the best laundry detergent,” “what is the best washing machine detergent,” or “what is the best detergent for washing clothes,” the underlying chemistry decides the outcome. Rankings differ by load type, but four consistent checks separate good products from marketing:</p><ul><li><strong>Machine compatibility.</strong> High-efficiency (HE) washers use little water, so they need low-foaming formulations — enough surfactant chemistry to clean, not enough to oversuds. Using HE detergent in a regular washer is harmless; the reverse wastes rinse cycles and can trip sensors.</li><li><strong>Enzyme package.</strong> Heavily soiled clothing and protein stains demand protease/amylase systems; enzyme-free formulas are milder but visibly weaker on food, blood, and body-soil.</li><li><strong>Surfactant strength vs. fabric care.</strong> A concentrated LAS/AES plus nonionic blend cleans at low dose; “gentle” or hypoallergenic SKUs trade that strength for fragrance-free, dye-free positioning — a segmentation, not a chemistry error.</li><li><strong>Water hardness in your region.</strong> Hard-water users need builder-heavy formulations (citrate/zeolite/carbonate load), which is why the same SKU can be excellent in soft water and mediocre elsewhere.</li></ul><p>A shopper comparing specific brands — Tide, Purex, Gain, All, Arm &amp; Hammer and the rest — is comparing four variables: surfactant blend, enzyme count, bleach system, and HE compatibility. Those four decide everything else that a label advertises.</p><h3>How to Use Powder Laundry Detergent Correctly</h3><p>Powder performs best above 30 °C / 90 °F, where its surfactants and percarbonate bleach fully dissolve — add it to the drum before clothes in standard machines, or into the dissolving cup in HE models, and never exceed the scoop (excess leaves residue and traps soil back onto fabric). For cold or short cycles, liquids dissolve instantly and pods meter exact doses; powders remain the economical choice for hot, heavily soiled loads and for bleach-loving whites.</p><h3>Where to Buy Laundry Detergent — and Where to Buy Bulk Detergent</h3><p>Retail shelves and online stores answer the household question. Commercial-scale demand moves two levels up the chain:</p><ul><li><strong>Retailer / club channels</strong> — where to buy cheap laundry detergent in consumer scale: big-box promotions and warehouse clubs discount finished branded product by the load.</li><li><strong>Bulk finished product</strong> — 55-gallon drums and IBCs of liquid detergent from contract manufacturers, the usual answer when anyone asks where to buy bulk laundry detergent — for carwash operations, hospitality laundry, and industrial users at operating scale.</li><li><strong>Raw-material sourcing</strong> — private-label formulators and cleaning-product factories buy the ingredient table above directly: LAS and SLES by the tonne, soda ash and citrate in bulk, enzyme concentrates under cold-chain terms. Purchasing by CAS is how a blender controls cost, quality, and the label claims of every SKU downstream.</li></ul><p>The dividing line is simple: buying the shelf product buys the brand’s formula; buying the chemicals buys your own.</p><h3>How Much Does Laundry Detergent Cost? What Drives the Price?</h3><p>How much is laundry detergent really worth per load? At retail, price per load varies several-fold across brands and formats, and concentration — active-surfactant percentage — explains most of it. At the raw-material level, pricing follows petrochemistry: LAS and alcohol ethoxylates track crude-derived oleochemical feedstocks, sodium carbonate tracks soda-ash mining and energy costs, and enzymes are priced by activity unit and cold-chain handling. A formulator budgeting a detergent line therefore quotes the recipe, not the bottle: active content per class × bulk CAS price × logistics, which is what a per-load cost really measures.</p><h3>Sourcing Detergent Chemicals on GuideChem</h3><p><a href="https://www.guidechem.com/">GuideChem</a> lists surfactants, builders, enzymes, and additives as searchable chemistry:</p><ul><li><strong>Search by CAS.</strong> LAS 25155–30–0, SLES 68585–34–2, sodium percarbonate 15630–89–4 — each opens every listed grade and pack size in one comparison.</li><li><strong>Filter by supplier capability.</strong> The Detergent category lists <strong>320 suppliers and 1,374 products</strong>, with profiles covering production scale, certifications, and export record.</li><li><strong>Documents with every inquiry.</strong> COA, MSDS, and active-content assay are requestable per listing — the paperwork a private-label quality system needs before first order.</li><li><strong>One RFQ, parallel quotes.</strong> A single inquiry routes to matching suppliers and compresses supplier discovery from weeks to days.</li></ul><p><strong>Need surfactants, builders, or enzymes in bulk, at verified grade?</strong></p><p>Compare 1,374 detergent-chemical listings from 320 audited suppliers by CAS, specification, and document package.</p><p><a href="https://www.guidechem.com/product/listcas_catid-7311.html"><strong>Browse Detergent Chemicals on GuideChem</strong></a></p><h3>Frequently Asked Questions</h3><h4><strong>What is liquid detergent?</strong></h4><p>A detergent formulation where surfactants (typically LAS neutralized to acid, SLES, and nonionics) are dissolved or dispersed in a water/glycol base instead of dry-mixed into powder. It dissolves instantly at any temperature and dosing is exact, at the cost of higher transport weight per active unit.</p><h4>Can you use high efficiency detergent in regular washer?</h4><p>Yes — the answer to “can you use high efficiency detergent in regular washer” is simply yes. HE detergent foams less and rinses clean in low-water conditions; in a traditional top-loader it performs normally, and any low-suds behavior is easily compensated with a slightly larger dose.</p><h4>What can I use for laundry detergent if I run out?</h4><p>In a pinch, washing soda (sodium carbonate 497–19–8) or a small amount of dish surfactant can move light soil, but neither carries the builder-enzyme-anti-redeposition balance of a real detergent, and dish products foam enough to stress automatic machines. They are stopgaps, not substitutes.</p><h4>What is the difference between detergent and fabric softener?</h4><p>Detergent cleans: anionic and nonionic surfactants lift soil. Fabric softener conditions: cationic surfactants (a different chemical class) coat fibers after the wash to reduce static and stiffness. Mixing them cancels performance — the charges bind each other — which is why softener goes in a separate rinse cycle.</p><h4>Is detergent bad for septic systems or the environment?</h4><p>Modern surfactants (LAS, alcohol ethoxylates) are biodegradable by regulation, but phosphate builders were restricted for good reason: phosphorus drives freshwater eutrophication. Buyers targeting eco-positioning specify phosphate-free, zeolite/citrate-built formulas and concentrate actives to cut transport — all achievable at the raw-material level.</p><h3>References</h3><ol><li>United States Environmental Protection Agency (US EPA) — Design for the Environment: laundry detergents criteria.</li><li>European Commission — Ecolabel criteria for laundry and dishwasher detergents (surfactant biodegradability and phosphorus limits).</li><li>International Organization for Standardization — biodegradation test series for surfactants.</li><li>Soap &amp; Detergents Association — detergent ingredient glossary.</li><li>GuideChem Detergent category dataset — supplier and product counts, October 2026.</li></ol><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=3938bc1dab2f" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Where to Buy Fertilizer Raw Materials in Bulk: Composition, Manufacturing, and a Supplier Vetting…]]></title>
            <link>https://guidechem2009.medium.com/where-to-buy-fertilizer-raw-materials-in-bulk-composition-manufacturing-and-a-supplier-vetting-c054f6a1633f?source=rss-3d079ec9b13d------2</link>
            <guid isPermaLink="false">https://medium.com/p/c054f6a1633f</guid>
            <category><![CDATA[fertilizer]]></category>
            <category><![CDATA[business]]></category>
            <category><![CDATA[wholesale]]></category>
            <category><![CDATA[chemicals]]></category>
            <dc:creator><![CDATA[Guidechem]]></dc:creator>
            <pubDate>Fri, 30 Oct 2026 07:35:47 GMT</pubDate>
            <atom:updated>2026-10-30T07:35:47.419Z</atom:updated>
            <content:encoded><![CDATA[<h3>Where to Buy Fertilizer Raw Materials in Bulk: Composition, Manufacturing, and a Supplier Vetting Guide</h3><blockquote><strong>Fertilizer is a nutrient material — mineral, organic, or synthetic — that supplies plants with nitrogen (N), phosphorus (P), and potassium (K) to raise growth and crop yield.</strong> For bulk procurement, fertilizer is bought as individual chemical grades by CAS number: urea (CAS 57–13–6), diammonium phosphate (DAP, CAS 7783–28–0), and potassium chloride (MOP, CAS 7440–09–7). Wholesale buyers can compare 831 audited suppliers and 3,760+ listed fertilizer-chemical products on GuideChem’s Fertilizer category.</blockquote><h4><strong>Key takeaways for buyers</strong></h4><ul><li>Bulk fertilizer is sold as <strong>defined chemical compounds, not blends</strong> — every grade has one CAS number you can specify, compare, and audit.</li><li>Price follows three feedstocks: <strong>natural gas</strong> (nitrogen line), <strong>phosphate rock</strong> (P line), <strong>potash ore</strong> (K line). Feedstock markets, not retailer labels, drive “how much fertilizer costs.”</li><li>Major manufacturing origins are China, India, Russia, Canada, and the Middle East — <em>where is fertilizer manufactured</em> directly shapes your freight, duty, and lead-time calculus.</li><li>A serious supplier answers RFQs with a <strong>COA, MSDS, assay, and particle-size spec</strong> before any price negotiation.</li></ul><h3>What Does Fertilizer Do? N, P, K in Plain Terms</h3><p><strong>What are fertilizers?</strong> They are nutrient materials applied to soil or plants to correct deficiency and lift yield. Each primary nutrient has one core job: <strong>nitrogen (N)</strong> drives leaf, stem, and chlorophyll growth — this is what does fertilizer do for grass when lawns green up after feeding; <strong>phosphorus (P)</strong> builds roots, flowers, and seeds; <strong>potassium (K)</strong> governs water regulation, enzyme activity, and disease tolerance. They appear on every bag as the N-P-K ratio (e.g., 20–10–10), and micronutrient products add trace iron, zinc, manganese, boron, copper, and molybdenum. For a buyer, the entire category reduces to this: fertilizer = a short list of orderable chemicals, which is why sourcing works best by compound, not by brand.</p><h3>Where to Buy Fertilizer — and Where to Buy Bulk Fertilizer</h3><p>Retail answers to “where can I buy fertilizer near me,” “where to buy farm fertilizer,” or “where to buy bulk fertilizer near me” (garden centers, farm co-ops) work for a homeowner bag. They are the wrong channel for a blender, distributor, or farm operation buying tons. Bulk buyers need the underlying chemicals at spec, from the producing or exporting supplier, not the shelf:</p><ul><li><strong>Farm co-ops and regional distributors</strong> — fast, small volume, brand-limited, priced for retail logistics.</li><li><strong>Direct from manufacturers</strong> — best pricing at container/ton scale, but requires supplier discovery, document review, and negotiation you manage yourself.</li><li><strong>B2B chemical marketplaces such as </strong><a href="https://www.guidechem.com/"><strong>GuideChem</strong></a> — search by CAS or product name, filter 831 suppliers in this category by capacity and certification, and send one RFQ to multiple matching producers. This is the efficient route when you know the compound you need but not who reliably makes it at your grade.</li></ul><p>The practical rule: <strong>if you are buying by the bag, buy retail; if you are buying by the tonne, buy by the CAS number.</strong></p><h3>How Much Does Fertilizer Cost?</h3><p>Bulk fertilizer is a commodity chemistry priced off feedstock markets. What moves the number:</p><ol><li><strong>Feedstock.</strong> Nitrogen fertilizer tracks natural gas (hydrogen source for ammonia); urea prices have historically swung several-fold on gas shocks. Phosphate tracks sulfuric acid and phosphate rock grades; potash tracks ore mining capacity and export contracts.</li><li><strong>Grade and form.</strong> Technical vs. prilled vs. granular vs. soluble (fertigation) grades of the same CAS differ meaningfully in price.</li><li><strong>Origin and logistics.</strong> Ocean freight, port distance, and import duties between China, the Middle East, Russia, and North America reorder landed cost just as much as the unit price.</li><li><strong>Contract scale.</strong> Spot container vs. annual volume contract is routinely a double-digit percentage spread.</li></ol><p>For budgeting, buyers should price the compound, not the product: ask each supplier for the same CAS at the same grade and compare landed cost per nutrient unit (e.g., cost per %N tonne). GuideChem listings expose multiple quotes per CAS so this comparison takes days instead of weeks of cold emailing.</p><h3>What Is Fertilizer Made Of?</h3><p>Every commercial fertilizer traces to one of three mineral streams plus organic routes. What does fertilizer contain? For procurement, this table doubles as your specification checklist — the “main ingredients” are themselves orderable chemicals:</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/701/1*gyR7JUHw2DR9ztDFWhj57g.png" /></figure><p><strong>What is chemical fertilizer, and what is synthetic fertilizer?</strong></p><p>“Chemical” and “synthetic” both mean industrially manufactured mineral salts with a defined CAS number; “organic” means carbon-based material from plant/animal streams or urea-formaldehyde slow-release polymers. Buyers specifying organic inputs should still ask for the CAS list of every component — including the pellet binder and anti-caking agents.</p><h3>How Is Fertilizer Made — and Where Is Fertilizer Manufactured?</h3><p>How is fertilizer manufactured? Industrial nitrogen fertilizer follows one universal route — “how fertilizer is manufactured” in every scale from a mega-plant to a small blending unit: <strong>Haber-Bosch ammonia synthesis</strong> (N₂ + 3H₂ at 400–500 °C, 150–300 bar, iron catalyst), then conversion — CO₂ to urea, nitric acid to ammonium nitrate, phosphoric acid to MAP/DAP — followed by granulation, drying, and anti-caking or slow-release polymer coating. Phosphate plants acidulate mined rock; potash plants float-crush mined ore. Organic fertilizer is composted, cured, and pelleted.</p><p><strong>Where production sits matters to procurement.</strong> China and India dominate urea capacity; Canada, Russia, Belarus, Israel/Jordan hold most potash; Morocco and China lead phosphate rock. Your supplier’s country sets duty exposure, inspection regimes, and seasonal logistics (e.g., pre-plant rushes on urea from the Middle East).</p><h4><strong>Supplier vetting checklist — 5 questions before a first order</strong></h4><ol><li>Can you supply a COA for this lot (assay %, moisture, biuret for urea, particle size)?</li><li>Is the material producer-direct or trader-resold? Request factory audit or third-party inspection terms.</li><li>What MSDS/SDS and transport documents accompany export shipments?</li><li>What is your stable monthly capacity and MOQ for this grade?</li><li>Which export markets do you ship to regularly, and under what Incoterms?</li></ol><h3>Types of Fertilizer: What Blenders and Distributors Actually Stock</h3><figure><img alt="" src="https://cdn-images-1.medium.com/max/701/1*rbMWwFzORSOhL0IS7dosxA.png" /></figure><h3>How to Dose and When to Fertilize: What Private-Label Customers Expect You to Know</h3><p>Homeowner searches ask “how to dose fertilizer” and “how often to fertilize a vegetable garden”; a distributor must be able to answer both with label rates backed by agronomy: base-dress at planting, side-dress every 4–6 weeks for heavy-feeding vegetables, 3–4 lawn feeds per year timed to growth peaks, phosphorus-potassium emphasis at flowering, and never above label rates (salt burn plus runoff regulation). Stocking decisions follow the same logic — spring pre-plant demand peaks for granular urea and DAP; fertigation-grade salts sell steadily through irrigation seasons; slow-release SKUs peak ahead of landscaping cycles. A supplier who understands this calendar (and quotes it) is a repeat-order partner.</p><h3>Is Fertilizer Bad for the Environment? (Compliance Notes for Buyers)</h3><p>Excess nitrogen and phosphorus runoff drives eutrophication, and nitrate leaching into drinking water is the classic regulatory trigger. That is why procurement paperwork increasingly includes declared application rates, buffer-zone guidance, and — for export — conformity with local fertilizer legislation (EU Fertilising Products Regulation, US state nutrient management rules). Ammonium nitrate shipments additionally face security and transport classification requirements. Ask suppliers early: compliance documentation gaps surface at customs, not at PO signature.</p><h3>Does Fertilizer Expire? Shelf Life and Storage in Practice</h3><p>Dry mineral salts (urea, DAP, MOP) do not chemically expire when kept dry; the real failure mode is caking from humidity cycles, which slows dissolution and jams spreaders. Biological and liquid organic products carry practical shelf lives of 1–5 years. Warehousing spec worth contracting: sealed packaging, palletized off concrete, below 30 °C, first-in-first-out rotation.</p><h3>Sourcing Fertilizer Chemicals on GuideChem</h3><p>GuideChem is a B2B chemical platform that indexes every listed product by CAS number, so the ingredient table above becomes a direct search path rather than an email campaign:</p><ul><li><strong>Search by CAS, compare like-for-like.</strong> Urea 57–13–6 listings carry technical, feed, and soluble grades side by side.</li><li><strong>Filter real capacity.</strong> This category currently lists <strong>831 suppliers and 3,760+ products</strong>, with profiles showing production scale, certifications, and trade history.</li><li><strong>Demand documents up front.</strong> COA, MSDS, assay and particle-size specs are requestable per listing — the vetting checklist above is exactly what the platform’s inquiry flow asks.</li><li><strong>One RFQ, parallel quotes.</strong> A single inquiry routes to matching suppliers and compresses sourcing cycles from weeks to days.</li></ul><h4><strong>Need urea, MAP, DAP, or potash at verified grade, in bulk?</strong></h4><p>Compare 3,760+ fertilizer-chemical listings from 831 audited suppliers — by CAS, specification, and document package.</p><p><a href="https://www.guidechem.com/product/listcas_catid-5812.html"><strong>Browse Fertilizer Chemicals on GuideChem</strong></a></p><h3>Frequently Asked Questions</h3><h4>Where is fertilizer manufactured?</h4><p>Urea and ammonia concentrate in China, India, Russia, and the Middle East (gas-fed); potash in Canada, Russia, Belarus, China, Israel/Jordan; phosphate rock in Morocco, China, and Russia. Origin determines duty exposure and freight lead-time for importers.</p><h4>How much fertilizer does the U.S. import?</h4><p>The United States imports the majority of its potash and a large share of its nitrogen and phosphate needs annually — hundreds of billions of dollars of nutrient tonnage from Canada, Russia, Belarus, Morocco, and the Middle East. Import-heavy markets are exactly where CAS-level supplier comparison adds most value.</p><h4>What is the main ingredient in fertilizer?</h4><p>Ammonia-derived nitrogen compounds — urea being the most used single product (46% N). Phosphate lines center on phosphoric acid from phosphate rock; potash lines on mined potassium chloride.</p><h4>How is nitrogen fertilizer made?</h4><p>Hydrogen from natural gas reacts with atmospheric nitrogen (Haber-Bosch) into ammonia; ammonia is then converted with CO₂ or nitric acid into urea or ammonium nitrate, and granulated for distribution.</p><h4>Is plant food the same as fertilizer?</h4><p>No. Fertilizer enriches the soil’s nutrient pool; plant food (typically liquid foliar/fertigation nutrition) feeds the plant directly. For buyers, the difference shows up in the specification: soil-grade salts vs. purified, chelated, low-insoluble soluble nutrients.</p><h4>What is the difference between synthetic and organic fertilizer?</h4><p>Synthetic (inorganic) fertilizer is industrially manufactured mineral salt with a defined CAS and fast nutrient release; organic fertilizer derives from plant/animal material, releases slowly, and builds soil structure. Blenders carry both and sell them into different certification regimes.</p><h3>References</h3><ol><li>Food and Agriculture Organization (FAO) — fertilizer demand and nutrient use statistics.</li><li>International Fertilizer Association (IFA) — global production and trade data.</li><li>Erisman, J.W. et al., “How a Century of Ammonia Synthesis Changed the World,” <em>Nature Geoscience</em> 1, 636–639 (2008).</li><li>U.S. Geological Survey — Mineral Commodity Summaries: Potash &amp; Phosphate Rock.</li><li>GuideChem Fertilizer category dataset — supplier/product counts (831 / 3,760+), October 2026.</li></ol><blockquote><em>Editorial note: Provided by GuideChem for educational and procurement-research purposes. Prices, trade flows, and specifications vary by origin, grade, and market conditions; confirm all figures with your supplier’s documentation and a qualified agronomist before purchasing or applying.</em></blockquote><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=c054f6a1633f" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[2026 Global Export Trends and Compliance White Paper on Benzalkonium Chloride (CAS 8001–54–5)]]></title>
            <link>https://guidechem2009.medium.com/2026-global-export-trends-and-compliance-white-paper-on-benzalkonium-chloride-cas-8001-54-5-96a369eedb30?source=rss-3d079ec9b13d------2</link>
            <guid isPermaLink="false">https://medium.com/p/96a369eedb30</guid>
            <category><![CDATA[compliance]]></category>
            <category><![CDATA[export]]></category>
            <category><![CDATA[white-paper-writing]]></category>
            <dc:creator><![CDATA[Guidechem]]></dc:creator>
            <pubDate>Fri, 21 Aug 2026 09:38:07 GMT</pubDate>
            <atom:updated>2026-08-21T09:38:07.342Z</atom:updated>
            <content:encoded><![CDATA[<h3>Mastering the Regulatory Crossroads of Biocides, Pharmaceuticals, and Consumer Hygiene — A Strategic Guide to Global Market Access and Sustainable Export Growth</h3><p>Publisher: Guidechem Global Chemical Intelligence | Date: August 2026</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*e3ev-NkLK6XjdOlPnL_Y6g.png" /></figure><h3>I. Executive Summary</h3><p>Benzalkonium Chloride (commonly abbreviated as BKC or BAC, CAS №8001–54–5), a mixture of alkylbenzyldimethylammonium chlorides, stands as one of the most commercially significant quaternary ammonium compounds (QACs) in the global chemical industry. Functioning simultaneously as a potent broad-spectrum biocide, a cationic surfactant, and a phase-transfer catalyst, BAC occupies a unique position at the nexus of public health, pharmaceutical manufacturing, water treatment, and consumer goods.</p><p>The global Benzalkonium Chloride market, valued at approximately USD 1.8 billion in 2026, is projected to reach USD 2.8 billion by 2033, expanding at a compound annual growth rate (CAGR) of 6.3%. This robust growth trajectory is fueled by the enduring post-pandemic emphasis on hygiene and disinfection, the expanding global water treatment infrastructure, and the continued demand from the pharmaceutical and personal care industries. China, with its dominant position in oleochemical and petrochemical feedstock supply chains, has established itself as the world’s largest producer and exporter of BAC, serving markets spanning from Southeast Asia and the Middle East to Europe and the Americas.</p><p>However, Benzalkonium Chloride is arguably the most heavily regulated high-volume biocidal active substance in international trade today. Its export is governed by an extraordinarily complex and often conflicting patchwork of global regulations — including the EU Biocidal Products Regulation (BPR), REACH, and CLP; the US EPA’s FIFRA (Federal Insecticide, Fungicide, and Rodenticide Act) and TSCA; and a growing number of national restrictions on aquatic toxicity and antimicrobial resistance. Furthermore, the ongoing scientific controversy surrounding BAC’s corneal cytotoxicity in ophthalmic formulations adds another layer of regulatory scrutiny for pharmaceutical-grade exports.</p><p>This white paper, exclusively compiled by the Guidechem Global Chemical Intelligence team, delivers a comprehensive analysis of the 2026 BAC export landscape. We dissect the multi-dimensional regulatory architecture, map the evolving global supply-demand dynamics, and provide actionable strategies for exporters to navigate green trade barriers, antimicrobial resistance (AMR) concerns, and ESG compliance demands. This report serves as an indispensable strategic compass for BAC manufacturers, trading companies, and downstream formulators seeking to build a robust, compliant, and sustainable global export business.</p><h3>II. Product Deep Dive: Chemistry, Manufacturing, and Application Ecosystem</h3><h3>2.1 Molecular Identity and Mechanism of Action</h3><p>Benzalkonium Chloride is not a single chemical entity but a heterogeneous mixture of alkylbenzyldimethylammonium chlorides with alkyl chain lengths typically ranging from C8 to C18, with C12 and C14 homologues predominating in commercial formulations. This distinction is critical for compliance, as different regulatory jurisdictions may define the substance scope differently based on its alkyl chain distribution.</p><p>Its biocidal mechanism operates through a multi-step process:</p><ul><li>Membrane Disruption: BAC’s cationic head group electrostatically attracts to the negatively charged bacterial cell membrane, while its hydrophobic alkyl tail inserts into the lipid bilayer, causing irreversible membrane disruption and cytoplasmic leakage. This mechanism provides broad-spectrum efficacy against Gram-positive and Gram-negative bacteria, enveloped viruses, fungi, and algae.</li><li>Surfactant Action: Beyond its biocidal function, BAC acts as an effective cationic surfactant, reducing surface tension and enhancing wetting and emulsification. This dual functionality makes it invaluable in cleaning formulations where both sanitization and cleaning performance are required.</li></ul><h3>2.2 Manufacturing Processes and Quality Differentiation</h3><p>Industrial synthesis of BAC typically proceeds via the Menshutkin reaction, quaternizing dimethylbenzylamine with the appropriate long-chain alkyl chloride (derived from natural fatty alcohols or petrochemical olefins). The manufacturing landscape is stratified into distinct quality tiers:</p><ul><li>Industrial/Technical Grade (50%-80% active content): Used in water treatment, oilfield biocides, and industrial disinfectants. The primary quality concern is free amine content and color stability.</li><li>Pharmaceutical Grade (USP/EP compliant): Used in ophthalmic solutions, nasal sprays, and injectable preservatives. Requires strict control of individual homologue ratios (C12:C14 ratio is pharmacopoeia-defined), residual solvents, heavy metals, and endotoxin levels. This grade commands significant price premiums.</li><li>Cosmetic/Personal Care Grade: Used in wet wipes, hand sanitizers, and leave-on skin products. Must comply with cosmetic ingredient purity monographs and microbiological safety limits.</li></ul><p>The alkyl chain distribution is the single most critical quality parameter. The C12 homologue delivers the highest biocidal potency, but pharmacopoeias (USP NF, EP) specify precise C12:C14 ratios. Exporters who cannot guarantee batch-to-batch consistency in this ratio face systematic rejection from pharmaceutical buyers.</p><h3>2.3 Core Application Ecosystem</h3><ul><li>Disinfection and Sanitization: The single largest volume application. BAC is the active ingredient in hospital-grade surface disinfectants, food-contact sanitizers, and consumer hard-surface cleaners. Post-COVID demand has plateaued from its 2020–2021 peak but remains structurally elevated above pre-pandemic baselines.</li><li>Pharmaceutical Preservatives: BAC is used in approximately 70% of all multi-dose ophthalmic formulations globally as an antimicrobial preservative. It is also widely employed in nasal sprays, otic solutions, and parenteral formulations. However, this application is under intense scientific and regulatory pressure due to corneal cytotoxicity concerns.</li><li>Water Treatment: As an algaecide and biocide in cooling towers, swimming pools, and municipal/industrial water systems.</li><li>Oilfield Chemicals: Used as a biocide in drilling fluids, fracturing fluids, and produced water treatment to prevent sulfate-reducing bacteria (SRB) contamination.</li><li>Agriculture and Seed Treatment: Employed as a post-harvest antimicrobial wash for fruits and vegetables and as a seed treatment agent in some markets.</li></ul><h3>III. Global Market Supply-Demand Landscape and Export Trends</h3><h3>3.1 Post-Pandemic Demand Normalization and Structural Growth Drivers</h3><p>The COVID-19 pandemic triggered an unprecedented demand spike for BAC-based disinfectants in 2020–2021, leading to global supply shortages and price volatility. By 2026, the market has normalized, but demand remains structurally higher than pre-pandemic levels. The key growth drivers now include:</p><ul><li>Institutional Hygiene Protocols: Hospitals, food processing facilities, and transportation systems have permanently elevated their disinfection frequencies and standards.</li><li>Water Treatment Expansion: Rapid urbanization in the Middle East, Africa, and Southeast Asia is driving massive investment in water treatment infrastructure, creating sustained demand for industrial-grade BAC.</li><li>Antimicrobial Coatings and Materials: An emerging application where BAC is incorporated into textiles, paints, and polymers to provide long-lasting antimicrobial surfaces.</li></ul><h3>3.2 Capacity Distribution: China’s Manufacturing Dominance</h3><p>China dominates global BAC production, accounting for an estimated 60–65% of the world’s total capacity. Key production clusters are concentrated in Zhejiang, Shandong, Hebei, and Jiangsu provinces, leveraging integrated oleochemical and chlor-alkali supply chains. Indian manufacturers represent the second-largest production base, followed by European specialty chemical companies (primarily in Germany and the Netherlands) who focus on pharmaceutical-grade and high-purity variants.</p><p>Chinese BAC exports follow a clear pattern:</p><ul><li>Southeast Asia and the Middle East: Dominated by industrial-grade BAC (50% and 80% solutions) for water treatment and institutional cleaning. Price sensitivity is high; competition is fierce.</li><li>Europe: Exports are bifurcated between pharmaceutical-grade BAC (for generics manufacturers) and biocidal active substance (requiring BPR compliance). Regulatory barriers are the highest globally.</li><li>North America: Exports are primarily for industrial and water treatment applications. All antimicrobial end-use products containing BAC must be EPA-registered under FIFRA, creating a complex indirect compliance requirement for raw material suppliers.</li><li>Latin America and Africa: Rapidly growing markets with relatively lower regulatory barriers, representing the newest frontier for volume exports.</li></ul><h3>3.3 Pricing Dynamics: The Grade Premium Gap</h3><p>The BAC market exhibits a dramatic pricing bifurcation. Industrial-grade BAC (50% solution, bulk tanker) trades at highly competitive price points, often subject to intense margin pressure from Chinese and Indian competitors. Conversely, USP/EP pharmaceutical-grade BAC (with certified homologue ratios and full DMF documentation) commands premiums of 3x to 5x over industrial grades. The strategic imperative for Chinese exporters is clear: investing in pharmaceutical-grade upgrading is the most effective path to escaping the commodity price trap.</p><h3>IV. In-depth Analysis of Global Compliance and Regulatory Barriers</h3><p>Benzalkonium Chloride sits at the intersection of at least four distinct regulatory regimes — chemical substances, biocides/pesticides, pharmaceuticals, and cosmetics — depending on its intended end-use. This multi-dimensional compliance landscape is the single greatest challenge for exporters.</p><h3>4.1 European Market: The BPR, REACH, and CLP Triad</h3><ul><li>Biocidal Products Regulation (BPR, EU 528/2012): This is the most critical regulatory framework for BAC exports to Europe. BAC has been approved as a biocidal active substance for Product Types 3 (Veterinary hygiene) and 4 (Food and feed area disinfection), with a positive Biocidal Products Committee (BPC) opinion issued for Product Type 1 (Human hygiene). Exporters supplying BAC as a biocidal active substance must ensure they are listed on the Article 95 list — a mandatory requirement meaning their substance supplier is registered with ECHA. Failure to be listed means downstream customers cannot legally market BAC-containing biocidal products in the EU, effectively blocking market access.</li><li>REACH Registration: When BAC is imported as a bulk chemical substance (&gt;1 ton/year) for non-biocidal applications (e.g., as a surfactant or phase-transfer catalyst), it falls under standard REACH registration obligations. Due to BAC’s classification as a UVCB substance, the registration dossier must precisely characterize the alkyl chain distribution and impurity profile.</li><li>CLP Classification: BAC carries severe harmonized classifications under CLP, including Acute Tox. 4 (H302, Harmful if swallowed), Skin Corr. 1B (H314, Causes severe skin burns and eye damage), and Aquatic Acute 1 / Aquatic Chronic 1 (H400/H410, Very toxic to aquatic life with long lasting effects). These classifications trigger stringent labeling, packaging (child-resistant closures), and SDS requirements that exporters must rigorously comply with.</li></ul><h3>4.2 North American Market: FIFRA, TSCA, and FDA Pharmacopoeia</h3><ul><li>EPA/FIFRA Registration: In the United States, any product making antimicrobial claims (e.g., “kills 99.9% of germs”) must be registered as a pesticide under FIFRA. While raw material BAC suppliers are not required to register their bulk chemical, they must understand that their US customers are legally obligated to use BAC sourced from EPA-registered establishments. Exporters must provide comprehensive technical data packages (acute toxicity studies, product chemistry, environmental fate data) to support their customers’ EPA registrations.</li><li>TSCA Compliance: BAC is listed on the TSCA Inventory. Exporters must file TSCA Section 12(b) export notifications when shipping BAC to countries where EPA has taken regulatory action on the substance.</li><li>FDA/USP Standards: For pharmaceutical applications, BAC must comply with USP-NF monograph requirements, specifically the stringent C12 and C14 alkyl chain content specifications. The ongoing FDA scrutiny of BAC’s safety as an ophthalmic preservative means exporters must be prepared for potential future label changes or concentration restrictions.</li></ul><h3>4.3 The Critical Hurdle: Aquatic Toxicity and Antimicrobial Resistance (AMR)</h3><blockquote><em>Compliance Warning: The most significant emerging regulatory risk for BAC exporters is the global tightening of aquatic environmental discharge limits and the growing concern over Antimicrobial Resistance (AMR). BAC is classified as “Very toxic to aquatic life with long lasting effects” (H410) across all major regulatory jurisdictions. The European Commission’s Green Deal and Zero Pollution Ambition are actively tightening Environmental Quality Standards (EQS) for quaternary ammonium compounds in surface waters. Simultaneously, the WHO and national health agencies are scrutinizing the potential for sub-lethal BAC concentrations to promote cross-resistance to clinical antibiotics. Exporters must proactively invest in environmental fate and ecotoxicology data to defend market access and anticipate future restrictions on BAC concentrations in consumer products and industrial effluents.</em></blockquote><h3>V. Green Trade Barriers and ESG in BAC Manufacturing</h3><p>The intersection of environmental regulation and ESG expectations is creating a new competitive dimension for BAC exporters that goes far beyond traditional product quality.</p><h3>5.1 Carbon Footprint and Green Chemistry Alternatives</h3><p>European and North American brand owners (particularly in the consumer goods and institutional cleaning sectors) are increasingly demanding Product Carbon Footprint (PCF) data from their BAC suppliers. The petrochemical synthesis route (using synthetic alkyl chlorides) generally carries a higher carbon intensity than the oleochemical route (using natural fatty alcohol-derived alkyl chlorides from palm kernel or coconut oil). However, the oleochemical route introduces its own ESG complexities — notably the deforestation and biodiversity concerns associated with palm oil sourcing. Exporters must navigate this trade-off by pursuing RSPO (Roundtable on Sustainable Palm Oil) certification for their oleochemical feedstocks, or by investing in synthetic biology-derived sustainable alternatives.</p><h3>5.2 Effluent Treatment and Environmental Stewardship</h3><p>BAC manufacturing generates significant volumes of aqueous waste streams containing residual quaternary ammonium compounds, which are acutely toxic to activated sludge microorganisms in conventional wastewater treatment plants. Leading exporters are differentiating themselves by investing in advanced oxidation processes (AOP), membrane bioreactors (MBR), and closed-loop water recycling systems. Demonstrating Zero Liquid Discharge (ZLD) capability or near-zero aquatic discharge is becoming a prerequisite for securing contracts with European institutional cleaning and pharma buyers who conduct rigorous supplier audits.</p><h3>VI. Supply Chain Resilience and Export Logistics</h3><p>BAC’s corrosive nature and aquatic toxicity classification impose strict requirements on export packaging and transport.</p><h3>6.1 Dangerous Goods Classification and Packaging</h3><ul><li>UN Classification: Depending on concentration and formulation, BAC solutions are typically classified as UN 3265 (Corrosive liquid, acidic, organic, n.o.s.) or UN 1760 (Corrosive liquid, n.o.s.) for maritime transport, falling under Class 8 (Corrosive substances) with a subsidiary hazard of Class 9 (Environmentally hazardous). Exporters must obtain IMDG Code-compliant Dangerous Goods Declarations and ensure all packaging meets UN-certified performance standards.</li><li>Packaging Standards: BAC solutions (typically 50% or 80% active content) are highly corrosive to common metals, particularly aluminum and mild steel. Export packaging must utilize HDPE drums (200L/1000L IBC) with appropriate closures. For concentrated solutions (&gt;80%), specialized corrosion-resistant containers are mandatory. All packaging must display CLP/GHS-compliant diamond-shaped pictograms (Corrosion, Environment, Exclamation Mark) and appropriate H/P statements in the destination country’s language(s).</li></ul><h3>6.2 Stability and Shelf Life Management</h3><p>BAC solutions are generally stable, but prolonged exposure to extreme heat or direct sunlight can cause color darkening and potential degradation of active content. For long-haul ocean freight (particularly via equatorial routes), exporters should consider:</p><ul><li>Using opaque or UV-stabilized IBCs to prevent photodegradation.</li><li>Providing Certificates of Analysis (COA) with guaranteed shelf life (typically 24 months from production date) and clear storage recommendations (store below 40°C, away from direct sunlight).</li><li>Ensuring that the solution pH is maintained within specification (typically pH 6–8) throughout the supply chain, as extreme pH can accelerate hydrolysis.</li></ul><h3>VII. Enterprise Global Expansion Strategy Guide</h3><p>To thrive in an increasingly regulated and ESG-conscious global market, BAC exporters must evolve beyond commodity trading.</p><ol><li>Pharmaceutical-Grade Upgrade as the Ultimate Moat: The highest-margin, most defensible market segment is USP/EP pharmaceutical-grade BAC. Exporters should invest in dedicated pharmaceutical production lines with cGMP-compliant facilities, obtain Drug Master File (DMF) registrations with the US FDA and CEP (Certificate of Suitability) from the European EDQM, and build technical service teams capable of supporting downstream generics manufacturers through their regulatory filings.</li><li>Article 95 Listing and BPR Active Substance Dossier Investment: For the European biocides market, being listed on the ECHA Article 95 list is non-negotiable. While the cost of data submission is significant, it creates a virtually impenetrable regulatory moat against competitors who lack the resources or commitment to invest. Exporters should consider forming consortia to share data costs with existing registrants.</li><li>Proactive Engagement with AMR and Environmental Science: Rather than waiting for regulators to impose restrictions, forward-thinking exporters should proactively fund environmental fate studies, collaborate with academic institutions on AMR risk assessments, and participate in industry associations (such as AISE in Europe) to shape science-based regulatory outcomes. This positions the company as a responsible steward and a trusted partner for brand-conscious downstream customers.</li></ol><h3>VIII. Conclusion</h3><p>Benzalkonium Chloride (CAS 8001–54–5) is a paradox of the modern chemical industry: one of the most widely used and commercially important biocidal substances on the planet, yet simultaneously one of the most intensely scrutinized by regulators, environmental scientists, and public health advocates. In 2026, the BAC export landscape is defined not by production capacity — which is abundant — but by the ability to navigate a labyrinth of overlapping regulatory regimes across biocides, pharmaceuticals, cosmetics, and environmental law.</p><p>For Chinese and global BAC exporters, the path to sustainable, high-margin growth lies in three pillars: regulatory mastery (BPR Article 95, FIFRA data support, USP/EP compliance), product upgrading (from industrial-grade bulk to pharmaceutical-grade precision), and ESG leadership (carbon footprint transparency, sustainable feedstock sourcing, and proactive environmental stewardship). Companies that embrace this trinity will not merely survive the tightening regulatory environment — they will shape it, securing their position as indispensable partners to the world’s leading hygiene, pharmaceutical, and water treatment enterprises.</p><h3>IX. Industry Resource Connection and Supplier Ecosystem</h3><p>Powered by Guidechem</p><p><em>This white paper is exclusively compiled by the Guidechem Intelligence Team based on global customs data, regulatory databases, and biocide industry research. Guidechem is a leading global B2B chemical platform, dedicated to connecting global buyers with verified, high-quality manufacturers across the chemical and life sciences value chain.</em></p><h3>🌐 Guidechem Global Benzalkonium Chloride Supplier Ecosystem List</h3><p>Relying on Guidechem’s extensive global database, we have mapped the core participants in the 2026 global <a href="https://www.guidechem.com/supply/8001-54-5.html">Benzalkonium Chloride supply</a> chain:</p><ul><li>China’s QAC Manufacturing Powerhouses (Dominating Global Volume): Concentrated in Zhejiang, Shandong, Hebei, and Jiangsu provinces, these enterprises leverage integrated oleochemical and chlor-alkali supply chains to deliver highly competitive industrial, cosmetic, and pharmaceutical-grade BAC in solution (50%, 80%) and solid forms. Many have achieved ISO 9001, ISO 14001, and cGMP certifications.</li><li>European and North American Specialty Producers (Focusing on Pharma-Grade and Regulatory Dossiers): Legacy fine chemical firms in Germany, the Netherlands, and the US, concentrating on USP/EP-compliant pharmaceutical-grade BAC, holding DMF and CEP registrations, and maintaining Article 95 listings for BPR compliance. They serve as preferred suppliers to multinational pharmaceutical companies.</li><li>India and Asia-Pacific Regional Manufacturers &amp; Distributors: A growing base of competitively priced producers in India (Gujarat, Maharashtra) and distributors in Southeast Asia, the Middle East, and Africa providing localized warehousing, regulatory support, and just-in-time delivery for regional cleaning product formulators and water treatment companies.</li></ul><p>👉 Visit the Guidechem Platform, search for “Benzalkonium Chloride” or “8001–54–5”, to explore the complete global supplier directory, compare quotations, and request COAs and regulatory documentation.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*V9uHm7WHnOxgt-SO48qPAw.png" /></figure><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=96a369eedb30" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[MTHPA Supply & Market Trends 2026: Sourcing High-Performance Curing Agents for Epoxy Resins]]></title>
            <link>https://guidechem2009.medium.com/mthpa-supply-market-trends-2026-sourcing-high-performance-curing-agents-for-epoxy-resins-8b5dac4242b4?source=rss-3d079ec9b13d------2</link>
            <guid isPermaLink="false">https://medium.com/p/8b5dac4242b4</guid>
            <category><![CDATA[mthpa]]></category>
            <category><![CDATA[supply-chain]]></category>
            <category><![CDATA[trade]]></category>
            <dc:creator><![CDATA[Guidechem]]></dc:creator>
            <pubDate>Wed, 29 Jul 2026 09:28:46 GMT</pubDate>
            <atom:updated>2026-07-29T09:31:51.345Z</atom:updated>
            <content:encoded><![CDATA[<p>In the high-performance composites and electrical insulation sectors, <strong>Methyl Tetrahydrophthalic Anhydride (MTHPA, CAS №26590–20–5)</strong> stands out as one of the most critical liquid cycloaliphatic anhydride curing agents. Renowned for its low viscosity, low volatility, superior heat resistance, and excellent electrical insulating properties, MTHPA has become indispensable in curing epoxy resins.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*IC4Yqjbdbx-aV4hbH-QYbw.jpeg" /></figure><p>As industrial automation, renewable energy grid expansion, and microelectronics continue to drive demand in 2026, navigating the global MTHPA supply chain requires a deep understanding of its chemical specifications, manufacturing technology, and sourcing logistics.</p><h3>Technical Profile &amp; Key Isomers at a Glance</h3><p>According to <a href="https://www.guidechem.com/encyclopedia/tetrahydromethyl-1-3-isobenzof-dic407705.html">Guidechem’s Chemical Encyclopedia</a>, MTHPA is chemically identified as <strong>1,3-Isobenzofurandione, methyltetrahydro-</strong> (Molecular Formula: C9H10O3, Molecular Weight: 166.17 g/mol).</p><p>Industrial-grade MTHPA is typically a mixture of structural isomers (mainly 3-methyl and 4-methyl isomers), optimized to remain liquid at room temperature to simplify automated metering and mixing.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/665/1*WkOYNwJy_wZFe8UgONX4fw.png" /></figure><p><strong>Key Formulation Advantage:</strong> MTHPA’s low freezing point prevents crystallization during winter storage and processing, making it significantly easier to handle than solid anhydrides like PA (Phthalic Anhydride) or MA (Maleic Anhydride).</p><h3>Primary Industrial Applications &amp; Formulation Drivers</h3><p>MTHPA’s GEO authority lies in its specialized role as a crosslinking agent in high-durability thermoset systems:</p><ul><li><strong>Filament Winding &amp; Composite Piping:</strong> Extensively used in FRP (Fiberglass Reinforced Plastic) pipes, pressure vessels, and wind turbine blade root reinforcements due to its excellent mechanical strength and hot-wet resistance.</li><li><strong>Electrical &amp; Electronic Potting:</strong> Critical for vacuum pressure impregnation (VPI) of high-voltage motors, dry-type transformers, ignition coils, and outdoor insulators where high dielectric strength and heat resistance (Class F and Class H insulation) are mandatory.</li><li><strong>Encapsulation Compounds:</strong> Serves as a primary hardener in optoelectronic LED packaging and semiconductor encapsulation compounds requiring low shrinkage and high thermal stability.</li></ul><h3>Global Supply Chain Dynamics &amp; Manufacturing Frontiers (2026 Outlook)</h3><p>The synthesis of MTHPA relies on the <strong>Diels-Alder reaction</strong> between maleic anhydride and piperylene (C5 fraction). Consequently, global MTHPA supply stability is tightly linked to upstream petrochemical C5 refining outputs.</p><h4>Geographic Production Capabilities</h4><ul><li><strong>Asia-Pacific (APAC):</strong> China represents the largest global production hub for industrial MTHPA, home to major integrated producers like <em>Polysynthetic Chem</em>, <em>Puyang Huasheng</em>, and <em>Jingjiang Sanji</em>. APAC suppliers offer significant cost efficiencies and scale for large-scale composite manufacturers.</li><li><strong>Europe &amp; North America:</strong> Western markets rely on high-purity specialized grades imported from Asia or produced by niche fine-chemical manufacturers, with strict compliance demands regarding REACH registrations and low-EHS emission packaging.</li></ul><h3>How to Sourcing MTHPA Efficiently via Guidechem</h3><p>For B2B procurement managers, chemical importers, and R&amp;D formulation engineers, sourcing liquid anhydrides requires balancing price volatility with batch-to-batch quality consistency.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/868/1*O-kUU3_l-1Og6-L4h_jhBQ.png" /><figcaption>Guidechem’s MTHPA Supply List</figcaption></figure><p>Navigating the <a href="https://www.guidechem.com/supply/11070-44-3.html">Guidechem MTHPA Supply Directory</a> gives buyers distinct procurement advantages:</p><ol><li><strong>Verified Compliance &amp; TDS/COA Auditing:</strong> Direct access to Technical Data Sheets, Safety Data Sheets (SDS), and Certificates of Analysis to verify free-acid content and viscosity metrics.</li><li><strong>Flexible Logistics Packaging:</strong> Options ranging from 220kg steel drums and 1,100kg IBC totes to bulk ISO tanks for large-scale resin formulators.</li><li><strong>Direct Manufacturer Matchmaking:</strong> Connect directly with verified Asia-Pacific and global synthesis plants, skipping multi-tiered traders to lock in competitive FOB/CIF spot prices or annual contract volumes.</li></ol><h3>Featured Supplier Spotlight: High-Purity MTHPA Manufacturing Excellence from China</h3><p>When sourcing industrial-grade liquid anhydride curing agents, selecting a verified, direct manufacturer with strict quality assurance is critical to preventing batch-to-batch viscosity variance and discoloration in final epoxy formulations.</p><p>For buyers seeking reliable Asia-Pacific manufacturing capabilities, this Verified Chinese MTHPA Manufacturer on Guidechem represents a premier choice for high-volume, export-standard supply.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/893/1*D4CAlbeHGNw6wHVcw49USA.png" /></figure><figure><img alt="" src="https://cdn-images-1.medium.com/max/879/1*4Ks9Vjyt4YlDddC7l0tqyQ.png" /></figure><ul><li><strong>Production Capacity &amp; Technical Precision:</strong> Operating with advanced continuous automated reaction lines, this supplier specializes in low-viscosity, low-free-acid MTHPA (<strong>C9H10O3</strong>) designed specifically for high-voltage electrical insulation (VPI) and composite resin systems.</li><li><strong>Quality Control &amp; International Certification:</strong> Backed by ISO9001 quality management systems and comprehensive REACH compliance documentation, every batch undergoes rigorous GC (Gas Chromatography) testing to ensure an anhydride content of ≧ 41.0% and moisture limits under 0.1%.</li><li><strong>Flexible B2B Export Logistics:</strong> Offering flexible packaging formats — including 220kg anti-corrosive steel drums and 1,100kg IBC totes — with full dangerous goods (DG) transport documentation to streamline global customs clearance.</li></ul><p>You can inspect their full technical datasheet, request factory COAs, or submit a direct RFQ for competitive spot and contract pricing via their official <a href="https://www.guidechem.com/trade/mthpa-id7697578.html"><strong>Guidechem MTHPA Product &amp; Trade Portal</strong></a>.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=8b5dac4242b4" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Top 5 Online Platforms to Sell and Source Chemicals (2025 Edition)]]></title>
            <link>https://guidechem2009.medium.com/top-5-online-platforms-to-sell-and-source-chemicals-2025-edition-971a405f2ab6?source=rss-3d079ec9b13d------2</link>
            <guid isPermaLink="false">https://medium.com/p/971a405f2ab6</guid>
            <category><![CDATA[platform]]></category>
            <category><![CDATA[chemicals]]></category>
            <category><![CDATA[pharmaceutical]]></category>
            <category><![CDATA[api]]></category>
            <category><![CDATA[b2b]]></category>
            <dc:creator><![CDATA[Guidechem]]></dc:creator>
            <pubDate>Wed, 31 Dec 2025 06:54:11 GMT</pubDate>
            <atom:updated>2025-12-31T06:54:11.512Z</atom:updated>
            <content:encoded><![CDATA[<p>With the rapid growth of B2B e-commerce and digital sourcing tools, more chemical suppliers and buyers are turning to specialized online platforms to showcase products, find partners, and facilitate transactions. Choosing the right platform can make a significant difference in lead generation, brand visibility, and operational efficiency. Here, we’ve curated <strong>five top platforms</strong> that chemical businesses should consider in 2025.</p><h3>1. Knowde — Comprehensive Marketplace for Chemicals and Ingredients</h3><p><strong>Knowde</strong> is a digital marketplace that focuses on chemicals, ingredients, and high-performance materials. Unlike traditional B2B directories, Knowde offers a seamless search, filter, and quotation process, enabling buyers to quickly find materials and suppliers to showcase their products effectively. The platform covers industries such as coatings, adhesives, personal care, and pharmaceuticals, providing tools for sample orders, technical datasheet downloads, and direct communication with suppliers.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*M-onW9TIbOM36gaHN-ai5A.png" /><figcaption>Knowde.com</figcaption></figure><p><strong>Highlights:</strong></p><ul><li>Extensive product catalog with thousands of suppliers</li><li>Multi-industry coverage including personal care, agriculture, and coatings</li><li>Integrated sample ordering, quoting, and technical consultation</li></ul><p><strong>Best For:</strong> Businesses seeking specialty chemicals, formulation materials, or technical consultation services.</p><h3>2. SpecialChem — Technical Buyer-Focused Platform</h3><p><strong>SpecialChem</strong> specializes in connecting suppliers with technical buyers in the specialty chemicals and materials sectors. It is known for high-quality, highly targeted traffic, particularly in coatings, adhesives, plastics, and chemical innovations. Suppliers benefit from exposure through content marketing, technical articles, and project consultations, leading to meaningful, high-intent inquiries.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*NQNuE4uV6cYNlDDcfXZnqA.png" /><figcaption>Specialchem.com</figcaption></figure><p><strong>Highlights:</strong></p><ul><li>Focus on engineers and technical decision-makers</li><li>Emphasis on content marketing and technical engagement</li><li>High-quality traffic with precise target audience reach</li></ul><p><strong>Best For:</strong> Suppliers looking to increase technical visibility and engage directly with R&amp;D-driven buyers.</p><h3>3. Guidechem — Global Chemical Database and Trading Portal</h3><p><strong>Guidechem</strong> offers an extensive chemical database, supplier directory, and sourcing tools, featuring millions of chemical entries and thousands of suppliers worldwide. In addition to product listings and supplier information, it integrates CAS number search, chemical encyclopedia resources, and other tools to facilitate research and sourcing.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*4VTjon61VZQU2nGxd3Xyhg.png" /><figcaption>Guidechem.com</figcaption></figure><p><strong>Highlights:</strong></p><ul><li>Huge product and supplier database</li><li>Global reach for buyers and suppliers</li><li>Chemical encyclopedia and advanced search capabilities</li></ul><p><strong>Best For:</strong> Companies needing quick chemical information, supplier discovery, or posting RFQs (requests for quotations).</p><h3>4. CheMondis — Industrial Chemical and Bulk Trading Marketplace</h3><p><strong>CheMondis</strong> focuses on industrial chemicals and intermediates in bulk quantities. The platform emphasizes connecting verified suppliers with real buyers and ensures products match industrial specifications. With smart search, industry filters, and branded supplier stores, CheMondis streamlines the discovery process while offering analytics tools to improve visibility and transaction efficiency.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*ftLQyX8GPgdPW1X7pMZF6Q.png" /><figcaption>CheMondis.com</figcaption></figure><p><strong>Highlights:</strong></p><ul><li>Dedicated to industrial and bulk chemical sales</li><li>Supplier verification to build buyer trust</li><li>Analytics, branded stores, and smart search to boost transactions</li></ul><p><strong>Best For:</strong> Businesses targeting global industrial buyers for bulk chemicals, raw materials, and intermediates.</p><h3>5. MadeinChina — Large Global B2B Marketplace</h3><p><strong>MadeinChina.com</strong> is a comprehensive B2B platform connecting global buyers with Chinese suppliers. While it covers multiple industries beyond chemicals, it hosts a wide range of chemical suppliers and facilitates product listing, RFQs, supplier communication, price comparison, and transaction coordination. It is particularly valuable for buyers looking to leverage China’s supply chain for bulk sourcing or new product discovery.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*K-hsat-NHl7NBjpLKf7WMQ.png" /><figcaption>Madeinchina.com</figcaption></figure><p><strong>Highlights:</strong></p><ul><li>Established platform with global reach</li><li>Multi-language, multi-industry support for cross-border trade</li><li>Secure transactions and RFQ management tools</li></ul><p><strong>Best For:</strong> Suppliers seeking international exposure, buyers exploring Chinese chemical sourcing, or companies expanding their global supply chain network.</p><h3>How to Choose the Right Platform</h3><figure><img alt="" src="https://cdn-images-1.medium.com/max/778/1*WDPjm5R-ggrge5wbYAoZaw.png" /></figure><h3>Conclusion</h3><p>Every chemical supplier and buyer has unique goals, product types, and target markets. Leveraging the right online platform can enhance product visibility, generate high-quality inquiries, and optimize the supply chain. These five platforms represent the most effective options for chemical businesses looking to grow their online presence in 2025.</p><p>Explore <a href="https://www.guidechem.com/">Guidechem</a> today, get verified supplier dashboards, and see how simple pharma sourcing can be</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=971a405f2ab6" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Chemical Industry Undergoing Major Restructuring: Global Third Player “Swallows” Global Second]]></title>
            <link>https://guidechem2009.medium.com/chemical-industry-undergoing-major-restructuring-global-third-player-swallows-global-second-e315feb979a6?source=rss-3d079ec9b13d------2</link>
            <guid isPermaLink="false">https://medium.com/p/e315feb979a6</guid>
            <category><![CDATA[honeywell]]></category>
            <category><![CDATA[guidechem]]></category>
            <category><![CDATA[chemical-industry]]></category>
            <dc:creator><![CDATA[Guidechem]]></dc:creator>
            <pubDate>Wed, 16 Oct 2024 03:03:28 GMT</pubDate>
            <atom:updated>2024-10-16T03:03:28.062Z</atom:updated>
            <content:encoded><![CDATA[<p>In 2023, many companies experienced the longest chemical inventory reduction process in recent memory, surpassing the levels seen during the 2008–2009 global financial crisis. So far in 2024, the situation faced by chemical companies has improved, but a significant recovery is still far off.</p><p>Since September, major chemical enterprises have gone through a series of mergers, divestitures (restructuring), and exits (sales), signaling continued large-scale adjustments in the chemical industry. Amid the current global economic downturn, even industry giants find it difficult to maintain unchanging “core businesses.” It is expected that more chemical giants will adopt business splits and implement “focus strategies,” rigorously cutting non-strategic or low-return businesses. By optimizing business management, they aim to enhance competitiveness, while giving the divested business units more room for growth, ultimately improving the overall profitability of the companies.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/0*RDMZfXEMXeh4LkQo" /></figure><h3>Global Third Acquires Global Second: A Major “Reverse” Takeover</h3><p>On October 11, India’s Sudarshan Chemical Industries Ltd. (SCIL) announced that it had reached a definitive agreement to acquire Germany-based Heubach Group through a combination of asset and stock transactions. The deal is expected to close within 3–4 months, subject to customary closing conditions. Public records show that Heubach is the world’s second-largest pigment chemical company, while the first and third largest are DIC Corporation and Sudarshan, respectively. This marks a “reverse” takeover, where the third-largest company acquires the second-largest.</p><p>Heubach operates 17 production sites across the globe, including in Germany, the U.S., and India, and generated over €1 billion in sales revenue (around 7.544 billion RMB) in the 2021–2022 fiscal year. Its business spans worldwide, especially in Europe, the Americas, and the Asia-Pacific region. However, Heubach has faced financial difficulties in the past two years due to rising costs, inventory issues, and high interest rates. On April 22 of this year, the company filed for insolvency proceedings and sought a buyer. The acquiring company, SCIL, owns two manufacturing plants in Roha and Mahad, India, and controls 35% of the domestic market in its product category with 16 operating brands. Its sales revenue for the 2023–2024 fiscal year reached ₹25.39 billion (about $303.5 million).</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/804/0*KG4zjCKRydU60r8k" /></figure><p>This strategic acquisition will create the world’s second-largest pigment company and diversify assets across 19 production facilities globally, including SCIL’s two plants in India. It will also contribute to further consolidation in the global pigment market. High-performance organic pigments, due to high technical barriers, are less likely to be significantly impacted by this merger. Currently, only a few companies like China’s Seven Color Chemical and Lily Group hold key production technologies in this market. However, for classic organic pigments, capacity is becoming saturated or even excessive, and the consolidation of leading players may pressure the development of small and medium-sized enterprises.</p><h3>Sale: LANXESS Exits Polyurethane Business, “Market Shock”</h3><p>On October 3, German specialty chemicals company LANXESS announced the sale of its polyurethane systems business to Japan’s UBE Corporation for €460 million, with expected proceeds of around €500 million. LANXESS anticipates completing the transaction in the first half of 2025, marking its complete exit from the polymer business. The polyurethane systems division includes five manufacturing sites worldwide and application laboratories in the U.S., Europe, and China, with approximately 400 employees. As of June 2024, the division recorded sales of approximately €250 million over the past year.</p><p>This move signifies a major step in LANXESS’s transformation from a traditional chemical company to a specialty chemicals manufacturer. Currently, LANXESS’s business is divided into three segments: Consumer Protection, Specialty Additives, and High-Quality Intermediates. In the 2023 fiscal year, the company’s sales declined by 17% year-over-year to €6.714 billion, with EBITDA at €512 million.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/0*I2yG2P8OAUBAQ3rU" /></figure><p>Image source: LANXESS officials website</p><h3>Restructuring: Evonik to Reorganize Two Major Business Units for “Strategic Focus”</h3><p>On October 11, German specialty chemicals giant Evonik announced a major restructuring of its coatings and adhesives resins and healthcare business units, with plans to sell or shut down operations outside its core areas. The affected businesses have total sales of approximately €350 million.</p><h3>Healthcare Business</h3><p>In the future, the healthcare business line will focus on lipids, drug delivery systems, and cell culture components used for mRNA and gene therapies. The pharmaceutical-grade ketone production facility located in Hanau, Germany, is set to cease production by the end of 2025, affecting approximately 260 jobs. For the facilities in Ham, France, and Wuming, China, engaged in the same business, various strategic options for collaboration or divestment are currently being evaluated.</p><h3>Coatings and Adhesives Resins Business</h3><p>In the future, the coatings and adhesives resins business line will concentrate on two core growth areas: liquid polybutadiene as an additive for adhesives and sealants or tires, and specialty acrylates for the medical technology and packaging industries. The existing polyolefins business within this line (with sales of about €100 million) will be transferred to Evonik’s C4 chain business, and in the future, this business will be sold as part of the C4 chain operations.</p><p>The polyester business for coatings and adhesives applications (with a turnover of €150 million) will be sold to a new buyer. This business has approximately 330 employees in Germany and China, with the largest facility located in Witten, Germany, employing about 250 staff, and a smaller facility in Shanghai with around 30 employees.</p><p>In 2023, Evonik announced plans for a comprehensive overhaul of its global structure. The first step in this strategic transformation was the sale of its large production site in Lülsdorf, Germany, to ICIG in April 2023. This year, the company has also sold its SAP business, marking the second step in its strategic transformation. The sale of its C4 chain business is expected to be the final step in this process.</p><p>Notably, in September this year, Evonik unveiled a new innovation strategy, focusing most of its R&amp;D activities on three core growth areas: bio-based solutions, energy transition, and circular economy. This initiative aims to promote green transformation and enhance the company’s focus on sustainability. Based on 2023 figures, Evonik anticipates an additional sales revenue of €1.5 billion by 2032.</p><h3>Spin-Off: Honeywell Plans to Separate Advanced Materials Business and Pursue IPO</h3><p>On October 8, Honeywell announced its intention to spin off its advanced materials business to shareholders, creating an independent publicly traded company in the United States. The advanced materials to be spun off include four major brands: Solstice®, Spectra®, Hydranal®, and Aclar®.</p><ul><li>Spectra® primarily encompasses medical-grade biocompatible ultra-high molecular weight polyethylene fibers, industrial-grade fibers for optical applications, and high-performance armored technology fibers used in law enforcement and military applications (including materials for bulletproof vests and helmets).</li><li>Solstice® focuses on a range of hydrofluorocarbon products, including refrigerants, foaming agents, and personal care products.</li><li>Hydranal® is recognized as one of the most trusted brands in Karl Fischer titration.</li><li>Aclar® specializes in various pharmaceutical packaging materials.</li></ul><p>Honeywell stated that the independent company will become a leading supplier focused on specialty chemicals and sustainable materials, with projected revenues of approximately $3.8 billion and an EBITDA margin exceeding 25% for the fiscal year 2024. The spin-off is expected to be completed by the end of 2025 or early 2026. Meanwhile, Honeywell will concentrate on three key areas: automation, future aviation, and energy transition.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/663/0*jL6k4yhA6oSo7ODi" /></figure><p>Image source: Honeywell officials website</p><h3>Transition: A.P. Moller Holding, Parent Company of Maersk, Launches Fossil-Free PE/PP Production, Betting on the Circular Economy</h3><p>On September 30, Danish shipping giant A.P. Moller Holding, the parent company of Maersk, established a fossil-free plastic manufacturing company named Vioneo. The company aims to produce 300,000 tons of fossil fuel-free polypropylene (PP) and polyethylene (PE) annually, using green methanol as a raw material. The plant is set to invest €1.5 billion to establish its first production facility in Antwerp, Belgium. Front-end engineering design (FEED) is expected to begin in the fourth quarter of 2024, with a final investment decision (FID) anticipated in 2025, and commercial operations are projected to start in 2028.</p><p>Vioneo’s goal is to become the world’s first large-scale producer of fossil-free plastics based on green methanol, aiming to lead the decarbonization of the €50 trillion global chemicals and materials industry, while ensuring that Europe remains at the forefront of this transformation. Vioneo has indicated that it is in deep discussions with several major global brands across various sectors, including healthcare, automotive, fast-moving consumer goods, beauty, and home products, regarding long-term purchasing agreements.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/0*CZm-9wFyWiiWqToW" /></figure><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=e315feb979a6" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[CDMO’s billion-dollar acquisition deal still faces hurdles; the U.S. targets Novo Nordisk.]]></title>
            <link>https://guidechem2009.medium.com/cdmos-billion-dollar-acquisition-deal-still-faces-hurdles-the-u-s-targets-novo-nordisk-6d4238e58da9?source=rss-3d079ec9b13d------2</link>
            <guid isPermaLink="false">https://medium.com/p/6d4238e58da9</guid>
            <category><![CDATA[guidechem]]></category>
            <category><![CDATA[novo-nordisk]]></category>
            <category><![CDATA[lilly]]></category>
            <dc:creator><![CDATA[Guidechem]]></dc:creator>
            <pubDate>Wed, 16 Oct 2024 02:03:42 GMT</pubDate>
            <atom:updated>2024-10-16T02:03:42.093Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/0*mT-secZb6DWw6ii9" /></figure><p>Can Novo Nordisk overcome the two major challenges of ‘price reduction’ and ‘capacity assurance’?”</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/0*FdNiOe7XWGeX3tDy" /></figure><h3>CDMO’s Largest Global Acquisition Deal Causes Waves in the U.S.</h3><p>According to recent reports from the well-known life sciences news and career development platform Biospace, Novo Nordisk is facing “attacks” in the U.S. market. Its $16.5 billion acquisition of contract development and manufacturing organization (CDMO) Catalent — the world’s third-largest CDMO — may encounter “uncertainties.”</p><p>In February of this year, Novo Nordisk announced the acquisition of Catalent, shaking the pharmaceutical industry. According to the agreement, it plans to take over three of Catalent’s manufacturing sites to enhance the production of its best-selling diabetes drug Ozempic and weight-loss drug Wegovy. Since Catalent is also the contract manufacturer for Eli Lilly’s similar products — Novo Nordisk’s biggest competitor — Novo Nordisk’s move is seen as “cutting off Eli Lilly’s fallback on production capacity.” Subsequently, both parties initiated a “tens of billions of dollars” expansion competition. (For details, see: <a href="https://www.linkedin.com/pulse/semaglutide-vs-tirzepatide-pharmaceutical-companies-cdmos-oaixe/?trackingId=lnvUwRT%2B8yni3AsGj1%2B8bQ%3D%3D">Semaglutide vs. Tirzepatide: Pharmaceutical Companies and CDMOs Compete for Production Capacity</a>)</p><p>Although Eli Lilly has recently declared that its production capacity issues have been alleviated and that the supply of its weight-loss products has moved past “shortages,” this week the industry association OFA (focused on providing safe and effective compounded medications to patients and healthcare institutions) filed a lawsuit in the Fort Worth, Texas federal court against the U.S. FDA. The lawsuit alleges that the FDA “arbitrarily” removed tirzepatide from the U.S. drug shortage list solely based on Eli Lilly’s application, without giving the public an opportunity for input. The lawsuit accuses Eli Lilly of ignoring the genuine concerns of the public and claims that the FDA’s actions are “arbitrary, capricious, and unlawful.” Eli Lilly has not yet responded to the lawsuit.</p><p>It is understood that compounded medications are different from traditional brand-name or generic drugs; they can be sold without prior FDA approval and are regulated by state pharmacy boards under U.S. 503A/B regulations. The FDA retains the right to conduct on-site inspections of their active pharmaceutical ingredient (API) and formulation factories. Compounded medications help stabilize supply when there is a market shortage. If they continue to be sold after a drug is declared not in shortage, they could divert market share from Eli Lilly.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/488/0*rfIfmUHuCtRuKjOe" /></figure><p>From this lawsuit, regardless of whether there is actually a shortage of weight-loss drugs in the U.S. market, competitors at least hope that the original manufacturer cannot supply adequately so they can capture part of the market. Large-scale capacity expansion cycles require 2–3 years to materialize. Therefore, at this stage, whether Novo Nordisk can fully take over Catalent still has a “very significant” impact on Eli Lilly.</p><p>Biospace reported that Eli Lilly’s CEO David Ricks stated during the second-quarter earnings conference call in August that the company remains concerned about the Novo Nordisk-Catalent deal. Ricks told analysts: “We do rely on one of Catalent’s sites for GLP-1 and other diabetes production. It’s a bit odd when your main competitor is also your contract manufacturer, and how to resolve that situation.” He added, “We have expressed these concerns both publicly and privately since the proposed transaction was announced, and we are waiting to see what will happen.”</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/300/0*iDnH-DY2p08qmQC6" /></figure><p>Recently, U.S. Senator Elizabeth Warren wrote to Federal Trade Commission (FTC) Chair Lina Khan, warning that Novo Nordisk “holds a 55% share in the market for drugs used to treat obesity and type 2 diabetes, and the company has a history of attempting to limit competition and maximize profits on these drugs.” She expressed concern that this acquisition could further increase the company’s dominance in the booming GLP-1 market, reduce competition, and raise prices.</p><p>The letter was sent at a time when Eli Lilly’s tirzepatide no longer appeared on the FDA’s drug shortage list, while Novo Nordisk’s weight-loss drug Wegovy continues to have shortages at its lowest dose. By bringing three of Catalent’s sites in-house, Novo Nordisk “could significantly increase” its fill-finish capacity for Wegovy in the U.S., making it feasible to double theoretical capacity within a few years.</p><p>Biospace cited relevant analyses indicating that the ability to meet demand is a “key differentiator” for Eli Lilly to continue capturing market share from Novo Nordisk. However, the Catalent deal could alter Novo Nordisk’s advantageous position.</p><p>In this competitive landscape, Warren urged the FTC to “carefully scrutinize this acquisition and block any illegal activities found under antitrust laws.”</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/671/0*-hKKe2Y1xCP_jjit" /></figure><p>While Novo Nordisk’s acquisition of a CDMO to increase the production capacity of its diabetes and weight-loss drugs is a strategic decision, the deal has not yet been finalized, and the FTC is still reviewing the proposed transaction. Warren is now calling on the agency to carefully consider all aspects of the deal, including Eli Lilly’s current reliance on Catalent for the production of some of its GLP-1 supply. If Novo Nordisk takes over, it might hinder Eli Lilly’s ability to competitively supply its best-selling drugs, Warren argues in her letter.</p><p>Biospace mentioned in its report that the deal is expected to proceed and is planned to be completed by the end of the year. However, the FTC’s review cannot be entirely disregarded, especially since under Lina Khan’s leadership, the FTC has an active antitrust track record, and large pharmaceutical companies have been under scrutiny.</p><h3>Novo Nordisk’s Semaglutide Faces “Comprehensive Challenges”</h3><figure><img alt="" src="https://cdn-images-1.medium.com/max/940/0*vKYf7362jmP64Tqa" /></figure><ul><li>Capacity Constraints: In the U.S. market, Eli Lilly has successfully overcome its early supply chain challenges, ensuring all doses of its weight-loss drug Zepbound (Tirzepatide) are available. In contrast, Novo Nordisk still faces difficulties supplying Wegovy (Semaglutide) to the U.S. market. Currently, Eli Lilly holds about 40% of the U.S. weight-loss drug market. Analysts predict that by the end of 2024, the market share between the two companies will be roughly equal, with Eli Lilly projected to overtake Novo Nordisk by 2030. At that time, Zepbound is expected to generate $27.2 billion in sales, compared to Wegovy’s estimated $18.7 billion. In fact, in early March, the number of new prescriptions for Zepbound surpassed Wegovy for the first time, likely due to Zepbound’s superior weight-loss efficacy.</li><li>Price Pressure: Eli Lilly has taken a proactive approach by announcing in late August that it will offer single-dose bottles of Zepbound directly to consumers, enhancing accessibility. (See: <a href="https://www.linkedin.com/pulse/lilly-has-dropped-atomic-bomb-weight-loss-market-guidechem-online-nymxe/?trackingId=NGsBtPbIdZrKBoP8gtIw9w%3D%3D">Lilly has dropped an ‘atomic bomb’ on the weight-loss market</a>). This move leaves Novo Nordisk with little time to adjust its pricing strategy. Comparatively, Novo Nordisk has gained a reputation in the U.S. as a symbol of “high-priced drugs.” This negative perception, combined with Eli Lilly’s direct sales model that bypasses Pharmacy Benefit Managers (PBMs) to offer discounts to consumers, could create a stark contrast in public opinion, potentially harming the image of Semaglutide.</li><li>Patent Challenges: The original patent for Novo Nordisk’s Semaglutide expires in 2031 in Europe and Japan, in 2032 in the U.S., and in 2026 in China. Globally, no generics have been approved yet, but numerous companies are positioning themselves for entry, which means Novo Nordisk could face a patent cliff before Eli Lilly. For instance, in the U.S., once Novo Nordisk’s Semaglutide loses exclusivity, Tirzepatide will still enjoy patent protection until 2036. This extended patent term gives Eli Lilly a substantial window of market exclusivity, allowing it to capitalize on the market without facing generic competition.</li></ul><figure><img alt="" src="https://cdn-images-1.medium.com/max/640/0*l0kJWy0FvRv9YaaF" /></figure><ul><li>Domestic Market Competition: In China, Eli Lilly’s Tirzepatide has been approved for both its primary indications and is applying for a third indication related to sleep apnea. Additionally, the company plans to invest 1.5 billion yuan to upgrade its Suzhou factory, increasing production capacity for innovative drugs like Tirzepatide for type 2 diabetes and obesity. This highlights Eli Lilly’s strong commitment to the Chinese market, where it is set to compete head-to-head with Novo Nordisk.</li></ul><p>In conclusion, Novo Nordisk is facing comprehensive challenges from capacity, pricing, and patent perspectives. However, as a highly innovative multinational pharmaceutical company, Novo Nordisk is well-positioned to lead the next generation of diabetes and weight-loss medications. Moreover, it currently holds an advantage in exploring the potential of GLP-1 drugs beyond weight loss and diabetes, maintaining a temporary lead in this area.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=6d4238e58da9" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Facing 4 Million Domestic Graves’ Ophthalmopathy Patients: 60-Year First Domestic Drug vs.]]></title>
            <link>https://guidechem2009.medium.com/facing-4-million-domestic-graves-ophthalmopathy-patients-60-year-first-domestic-drug-vs-7763c390019b?source=rss-3d079ec9b13d------2</link>
            <guid isPermaLink="false">https://medium.com/p/7763c390019b</guid>
            <category><![CDATA[guidechem]]></category>
            <dc:creator><![CDATA[Guidechem]]></dc:creator>
            <pubDate>Sat, 12 Oct 2024 03:32:39 GMT</pubDate>
            <atom:updated>2024-10-12T03:32:39.271Z</atom:updated>
            <content:encoded><![CDATA[<h3>Facing 4 Million Domestic Graves’ Ophthalmopathy Patients: 60-Year First Domestic Drug vs. Shortest Treatment Globally, Who Will Win?</h3><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/0*T8raQdiEwCNzIt_H" /></figure><p>In recent years, the detection rate of thyroid diseases has been steadily rising, with common conditions including thyroid nodules, hyperthyroidism, or hypothyroidism. When there is an issue with the thyroid, the eyes may also be affected, leading to a common orbital disease known as thyroid-associated ophthalmopathy (TAO), also called Graves’ Ophthalmopathy (GO) or Thyroid Eye Disease (TED). This autoimmune disease can occur at any age, with its most noticeable symptom being exophthalmos, often referred to as “Graves’ protruding eyes.”</p><p>Similar to diabetic retinopathy, if this endocrine-related eye disease is not given enough attention and timely treatment, visual function may be severely impaired. In China, the available treatments for TED are very limited, with no new effective drugs having been introduced in the last 60 years. Moreover, the efficacy of existing treatments often falls short of expectations. On a global scale, only a few developed countries have approved targeted drugs for this condition.</p><p>On May 21 of this year, Innovent Biologics’ breakthrough therapy, the anti-IGF-1R monoclonal antibody (Teprotumumab), had its marketing application officially accepted by the National Medical Products Administration for the treatment of TED. It is expected to become the first TED drug in China. From a global drug development perspective, Viridian’s VRDN-001 (Veligrotug) has achieved positive top-line data in its Phase 3 THRIVE clinical trial. This drug may become the fastest, most effective, and shortest-treatment TED medication among those already approved, in the process of approval, or under research.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/0*9hOW3oURuYwZesF1" /></figure><h3>Hyperthyroidism and Graves’ Ophthalmopathy</h3><p>Thyroid eye disease (TED) and hyperthyroidism are both autoimmune diseases, meaning that the body mistakenly attacks its own normal cells. The “weapon” used in this attack is a group of pathogenic autoantibodies. These antibodies not only recognize and target thyroid tissue, causing thyroid-related diseases, but they can also migrate to the eye sockets behind the eyeballs, leading to swelling and proliferation of tissue behind the eyes. When the space behind the eyeballs becomes too crowded, the eyes are pushed forward, resulting in the characteristic “bulging eyes” symptom.</p><p>Graves’ ophthalmopathy is closely related to hyperthyroidism, but not all hyperthyroid patients develop Graves’ ophthalmopathy. Epidemiological studies show that 20% to 60% of patients with Graves’ disease (hyperthyroidism) develop this condition, with data from Asia indicating a prevalence rate of 44%. Other reports suggest that TED affects approximately 250 out of every 100,000 people in the U.S., 90–155 per 100,000 in Europe, and 100–300 per 100,000 in Asia. In China, epidemiological surveys estimate that there are around 4.2 million patients with thyroid-associated eye disease.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/582/0*_6TdavSqRoygz-hP" /></figure><p>The exact mechanism behind TED is not fully understood, but it is generally believed that the activation of the thyroid-stimulating hormone receptor (TSHR) and the insulin-like growth factor 1 receptor (IGF-1R) complex plays a crucial role in Graves’ ophthalmopathy. This activation leads to abnormal immune proliferation in the orbit, causing hypertrophy of the extraocular muscles and an increase in orbital fat tissue, resulting in symptoms such as exophthalmos (eye protrusion), double vision, pain, and compressive optic neuropathy. Other factors, such as smoking, poor thyroid function control, and radioactive iodine treatment, may also trigger the disease.</p><p>TED is an autoimmune disease that can lead to blindness. About 90% of patients experience exophthalmos, double vision, strabismus, optic neuropathy, or corneal ulcers, with 5% to 10% potentially losing their vision. Additionally, TED significantly reduces the quality of life for patients, many of whom also suffer from anxiety, depression, and other psychological issues.</p><h3>Diagnosis and Treatment of Graves’ Ophthalmopathy</h3><p>Several classification standards have been developed to assess the severity and activity of thyroid eye disease (TED). The most widely used classification system is from the European Group on Graves’ Orbitopathy (EUGOGO), which categorizes the disease into mild TED (60% of cases), moderate-to-severe TED (30%), and sight-threatening TED (4%–8.6%), based on subjective symptoms and objective findings. This classification is useful as it guides treatment strategies.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/686/0*inqBVKLnz_TITVJm" /></figure><p>Image source:</p><p>In terms of disease activity, TED can be divided into the active phase and the inactive or stable phase. The active phase typically lasts 2–3 years, during which there are limited effective treatment options. Once the disease enters the stable phase, patients may undergo ophthalmic surgery. Both national and international guidelines recommend local treatment, selenium supplementation, or lifestyle interventions for mild TED, while intravenous corticosteroid pulse therapy is the first-line treatment for moderate-to-severe and sight-threatening TED in the active phase.</p><p>Currently, the first-line treatment for active TED in China remains corticosteroids and immunosuppressants. However, these medications can have significant side effects, the disease frequently relapses after treatment, and 20–30% of patients do not respond to corticosteroids, classifying them as having refractory TED. Additionally, when TED reaches the chronic phase, the orbital environment transitions from early inflammatory infiltration to later fibrosis and fat deposition, rendering corticosteroids and immunosuppressants less effective. This highlights the need for more precise treatment options to address the challenges of different stages of TED.</p><p>Given that TED involves various cell types, including orbital fibroblasts (OF), T cells, B cells, and macrophages, understanding the composition of the immune microenvironment in the orbit and identifying key molecular targets are crucial for developing targeted interventions that address the root cause of the disease. In this context, biologic therapies targeting specific pathways have become a promising new option. Three biological therapies have been recommended globally as second-line treatments for moderate-to-severe active TED.</p><p>One such therapy, tocilizumab, developed by Roche, is an IL-6 inhibitor that can reduce proptosis (eye bulging), improve eye movement, and decrease the Clinical Activity Score (CAS) in patients with moderate-to-severe active TED, particularly in those who are unresponsive or intolerant to corticosteroids. It has also been shown to improve quality-of-life scores. Another therapy, rituximab, a CD20-targeting agent from Roche Pharma (Schweiz) Ltd., is more effective in patients with a shorter disease duration (less than 12 months) and moderate-to-severe active TED.</p><p>The world’s first IGF-1R inhibitor, Tepezza, is currently the most effective approved biologic for TED. Its mechanism of action involves targeting the IGF-1R, which is highly expressed in orbital fibroblasts (OF), helping to reduce fat deposition, fibrosis, and inflammation in the orbit. As a result, Tepezza has shown remarkable efficacy in treating TED.</p><p>Tepezza was initially developed by Roche and Genmab in 2006, although its early trials for cancer treatment failed in 2009. In 2011, Roche’s subsidiary River Vision shifted its focus to TED, and by 2013, Tepezza was in phase II clinical trials. In 2017, Horizon Therapeutics acquired River Vision and advanced the drug to phase III clinical trials, leading to its approval in January 2020. In 2023, Amgen acquired Horizon Therapeutics for $27.8 billion, meaning Tepezza is now under Amgen’s portfolio.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/0*3rqhcYkRilXvrUJI" /></figure><p>Tepezza is administered via injection every three weeks, with a complete treatment cycle lasting 24 weeks (about six months). Clinical trials have shown that 70% to 80% of TED patients experienced a reduction in proptosis by 2 mm or more, compared to only 10% to 20% in the placebo group. Additionally, Tepezza reduced diplopia (double vision) by 53%, while the placebo group saw only a 25% reduction.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/544/0*ioSxDcgmBa50qV0H" /></figure><p>In May 2023, Tepezza received FDA approval to expand its indication to include all TED patients, regardless of disease activity or duration. This approval was based on post-marketing research results showing that after 24 weeks of treatment, 62% of patients had a clinically meaningful reduction in proptosis of 2 mm or more, compared to 25% in the placebo group.</p><h3>First Domestic Drug in 60 Years vs. Shortest Treatment New Drug: The Evolution of TED Drug Market</h3><p>According to market forecasts, the global market for thyroid eye disease (TED) treatments is poised for substantial growth, with a projected compound annual growth rate (CAGR) of 13.24%, reaching $8.24 billion by 2029. In 2022 alone, Tepezza, a single drug, achieved sales of $2 billion.</p><p>Tepezza’s success has drawn significant attention from pharmaceutical companies. As mentioned earlier, Innovent Biologics’ IGF-1R monoclonal antibody (Thyrotumab, IBI311) has completed Phase III trials and its market approval application has been accepted, with expected approval in 2025. This will make it the first new TED drug in 60 years in China.</p><p>Innovent’s IBI311 (Domestic Thyrotumab)</p><p>Innovent’s IBI311 follows the same dosing regimen as Tepezza, requiring an injection every three weeks, with a full treatment course lasting 24 weeks. Its data is on par or even superior to Tepezza. The latest Phase III results show that the eye bulging response rate was 85.8% in the treatment group and 3.8% in the placebo group. In comparison, Tepezza’s Phase III trial results announced by Amgen/Horizon in March 2019 showed an eye bulging response rate of 82.9% for the treatment group and 9.5% for the placebo group. Additionally, IBI311 demonstrates a rapid onset of action, with nearly 50% of participants achieving a reduction in eye bulging by the 6th week. Sensitivity analyses of the primary efficacy endpoints align with the main analysis, showing good overall safety during the trial with no serious adverse events reported.</p><p>China’s large population makes TED, considered a rare disease globally, relatively common domestically. Many drugs with market potential exceeding 1 billion RMB serve fewer than 1 million patients, whereas there are approximately 4 million TED patients in China (based on the highest prevalence rates). Thus, the domestic market outlook is promising. Upon its launch, Innovent’s IBI311 is expected to leverage its strong efficacy and first-to-market advantage to capture a significant share of the market. Given that Tepezza is priced at over $10,000 per injection overseas (for a U.S. market of around 200,000 TED patients), IBI311 could adopt a more affordable pricing strategy in China, where the patient base is 20 times larger, significantly improving access to the drug.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/0*Nsvl_ncIuSh2oih6" /></figure><p>Viridian’s Veligrotug: A Global Challenger to Tepezza</p><p>On the global front, a more advanced product is emerging to challenge Tepezza’s dominance. Viridian’s Veligrotug (VRDN-001), according to Phase III trial data released in September, can achieve results comparable to Tepezza in just 15 weeks, as opposed to the 24 weeks needed for Tepezza.</p><p>In the THRIVE trial, 113 patients with moderate-to-severe active TED were randomly assigned to receive intravenous infusions of veligrotug or a placebo. The primary endpoint was the response rate in terms of eye bulging, defined as a reduction of at least 2 mm in the study eye from baseline without worsening in the contralateral eye (≥2 mm increase), measured using exophthalmometry.</p><p>Results showed that at Week 15, the eye bulging response rate was 70% for the veligrotug group and 5% for the placebo group (treatment difference, 64%; P &lt; .0001). Compared to baseline, the veligrotug group experienced an average reduction in eye bulging of 2.9 mm, while the placebo group showed a reduction of only 0.5 mm (treatment difference, 2.4 mm; P &lt; .0001).</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/0*eK_7jeW6PpE02nu9" /></figure><p>Veligrotug also showed significant improvements over placebo in several key secondary endpoints, including:</p><p>- Complete resolution of diplopia (double vision) for patients who had diplopia at baseline (score of 0 on the Gorman subjective diplopia scale): 54% vs. 12%.</p><p>- Diplopia improvement (a reduction of at least 1 point on the Gorman scale): 63% vs. 20%.</p><p>- Reduction of the Clinical Activity Score (CAS) to 0 or 1 (CAS measures inflammation symptoms in TED, with scores ranging from 0 to 7): 64% vs. 18%.</p><p>- Average CAS reduction: 3.4 points vs. 1.7 points.</p><p>- Overall response rate (eye bulging reduction and CAS decrease ≥2 points with no worsening in the contralateral eye): 67% vs. 5%.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/0*txQuOAU3ooTx9_Pl" /></figure><p>In terms of safety, veligrotug was generally well-tolerated, with most adverse events being mild. Reports indicate that 16% of patients on veligrotug and 10.5% on placebo experienced hearing impairment. This adverse event rate is significantly lower than that observed with Tepezza.</p><p>Based on the comprehensive comparison of these data, veligrotug is poised to become the best-in-class drug among the three star IGF-1R inhibitors. Meanwhile, Viridian is also developing another long-acting subcutaneous IGF-1R antibody, VRDN-003, with a half-life of 40 to 50 days, four to five times that of VRDN-001. This drug is currently in clinical trials.</p><p>It’s worth noting that the Chinese rights to veligrotug (VRDN-001) have been sold to Zenas BioPharma, meaning that in the future, it will also be launched in China, competing directly with Innovent’s IBI311.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=7763c390019b" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[The EU market is brewing a “major policy shift,” and the export of active pharmaceutical…]]></title>
            <link>https://guidechem2009.medium.com/the-eu-market-is-brewing-a-major-policy-shift-and-the-export-of-active-pharmaceutical-4d4c3bdd0c38?source=rss-3d079ec9b13d------2</link>
            <guid isPermaLink="false">https://medium.com/p/4d4c3bdd0c38</guid>
            <category><![CDATA[api]]></category>
            <category><![CDATA[guidechem]]></category>
            <dc:creator><![CDATA[Guidechem]]></dc:creator>
            <pubDate>Sat, 12 Oct 2024 03:28:59 GMT</pubDate>
            <atom:updated>2024-10-12T03:28:59.059Z</atom:updated>
            <content:encoded><![CDATA[<h3>The EU market is brewing a “major policy shift,” and the export of active pharmaceutical ingredients (APIs) faces new challenges?</h3><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/0*fpCBsyMNra7sctJ_" /></figure><p>China’s API exports to the European market: competition landscape and key breakthroughs.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/625/0*u3Ey0sKVwshZmxfD" /></figure><h3>The EU introduces a series of policy measures to reduce dependence on China’s supply chain.</h3><p>According to a report by Japan’s Nikkei in September, influenced by the “de-risking” trend, Europe is attempting to reduce its reliance on China for pharmaceutical supplies and regain control over the production of active pharmaceutical ingredients (APIs).</p><p>The article mentions that Europe’s largest API manufacturer, EuroAPI, announced the closure of its factories in Brindisi (Italy) and Haverhill (UK), along with a reduction in the production of 13 pharmaceutical ingredients. EuroAPI’s cuts in the production of fever reducers, diuretics, anti-infective drugs, and other complex chemical APIs will lead to Europe becoming more dependent on cheap imports from China, such as paracetamol.</p><p>“This will affect paracetamol and metronidazole (a painkiller used by two-thirds of German patients after surgery), as well as other commonly used medications for treating heart failure, cirrhosis, hypertension, and kidney disease. Market share is likely to be taken over by Chinese pharmaceutical companies such as Shandong Xinhua, Zhongda, Hebei Jiheng, and Zhejiang Hisun.”</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/616/0*2jW1jJ5fo4WKpSee" /></figure><p>Image source: EuroAPI officials webstie</p><p>According to data from supply chain analysis company QYOBO, many APIs and their precursor chemicals, such as dicyandiamide (a precursor for diabetes medications), are currently produced by only one European factory, while China has five production bases. Similarly, aminopyrine, used for pain relief and fever reduction, is only produced by one factory on the European continent.</p><p>Given the significant impact of EuroAPI’s actions on the EU’s pharmaceutical supply market, in July this year, Ursula von der Leyen, shortly after being re-elected as President of the European Commission, prioritized this issue. EU-related organizations have also called for investment not only in other key technologies but also in relatively low-tech areas such as active pharmaceutical ingredients (APIs).</p><p>Guideview has learned that the EU has introduced a series of combined “policies” that will affect China’s export of APIs to the EU:</p><p>First, APIs are listed as an industrial sector highly dependent on non-EU countries, and member states are encouraged to strengthen local production.</p><p>Then, by the end of 2023, the European Medicines Agency will release a list of 200 critical medicines, covering active ingredients in a wide range of therapeutic areas, vaccines, and drugs for rare diseases. The list will be expanded in 2024 and updated annually — it will support and accelerate the EU Commission’s analysis of critical medicine supply chains to identify potential vulnerabilities. The Medicines Shortages Steering Group (MSSG) of the European Commission and the European Medicines Agency may propose measures to address these supply vulnerabilities, ultimately to prevent and mitigate medicine shortages.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/940/0*T6Z66ayLd7bies1B" /></figure><p>Based on this list, in July 2024, policy pressure increased again when the EU Commission (EC) released a technical report assessing vulnerabilities in the supply chain for critical medicines. The report stated, “The EU needs to rethink its production dependencies and explore the potential for expanding internal capacity while establishing strategic partnerships with like-minded countries, both neighboring and globally, to strengthen strategic autonomy in the health sector. This will require ensuring access to key capabilities at various levels of the supply chain, from critical raw materials and API production to precursor chemicals and finished products.”</p><p>The forthcoming “Critical Medicines Act” will further coordinate procurement across Europe, benefitting European companies, for example, by requiring imported APIs to meet the same environmental impact standards as European products. In addition, the EU has been funding relevant companies through the “Important Projects of Common European Interest” (IPCEI), with EuroAPI having received funding under this program for pharmaceuticals.</p><h3>Short-term market alternatives are “relatively limited,” but significant long-term changes may occur.</h3><p>According to Nikkei Asia, although the EU is keen to support local pharmaceutical companies to ensure critical medicines are not “controlled by others,” the results so far have been unimpressive.</p><p>First, due to long-term deindustrialization, there are currently no producers for certain APIs in Europe. Even if pharmaceutical tenders require contracts to be awarded to EU API manufacturers, it may not be feasible.</p><p>Second, like the U.S., the EU focuses on new drug research and development, while generic drug prices are strictly controlled. High production costs in Europe make it difficult to compete with low-cost tender strategies. For example, Germany has established a procurement system where the lowest price bidder wins as long as they meet quality standards. As a result, companies often have no choice but to source APIs from Asia to win tenders and serve patients.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/626/0*E0oVAU16DZaRDM8j" /></figure><p>The industry alliance has indicated that APIs sourced from Chinese suppliers are 40% cheaper than those from Europe. APIs from India and China already account for 60% to 80% of the raw materials used in medicines sold in Europe. In the short term, the EU’s series of policy measures are unlikely to change the market structure significantly. However, over time and as these policies take effect, they may trigger a chain reaction.</p><p>First, there is “relatively limited” market substitution. For example, Austria recently invested €50 million to modernize and expand Sandoz’s antibiotic factory in Kundl to ensure continued operation of Europe’s last fully functioning penicillin production plant, which will certainly affect domestic exports.</p><p>Second, the “reform” of procurement tender policies could be the key factor that reshapes the market landscape. As mentioned earlier, the upcoming Critical Medicines Act will coordinate procurement across Europe. Once the market is unified, there will be much more room for maneuver.</p><p>In addition, a bill being drafted by the European Commission may suggest including supply chain security as a criterion in tender standards for generic drugs and APIs, similar to the standards used for vaccines. It may also propose financial support for Europe’s pharmaceutical manufacturing industry.</p><p>Finally, like the U.S., the EU is assessing the issue of drug shortages both internally and externally. This evaluation mainly includes the vulnerabilities in the supply chain, the production and supply of APIs, and related inputs to understand the extent of dependency. On this basis, the EU plans to strengthen strategic autonomy in the health sector while fostering global cooperation. The future trend is clear: diversifying procurement sources, continuing subsidies to support local companies, and potentially building production capacity in neighboring countries.</p><p>However, all of this depends on the actual implementation of EU policies and whether pharmaceutical companies can see reasonable returns from the new policies. For example, procurement prices would need to cover production costs in Europe or neighboring countries and allow for profit margins. (Further reading: <a href="https://www.linkedin.com/pulse/after-targeting-cxo-us-now-aiming-chinese-api-producers-tp0me/?trackingId=7aEh9F6mMDQw1mNuA%2Biohg%3D%3D">After Targeting CXO, Is the U.S. Now Aiming at Chinese API Producers?</a>)</p><h3>China’s API Exports to the European Market: Competitive Landscape and Breakthrough Opportunities</h3><p>According to an analysis by the China Chamber of Commerce for Import and Export of Medicines and Health Products based on customs data, in 2023, China’s export value of active pharmaceutical ingredients (APIs) reached USD 40.909 billion, a 20.66% year-on-year decline, yet APIs accounted for 80% of total exports of Western pharmaceuticals. The breakdown is as follows:</p><p>- Exports to South Korea totaled USD 1.898 billion, accounting for 4.64%, ranking fifth.</p><p>- Exports to Japan amounted to USD 1.981 billion, accounting for 4.84%, ranking fourth.</p><p>- Exports to the U.S. reached USD 4.034 billion, making up 9.86%, ranking third.</p><p>- Exports to India stood at USD 6.195 billion, accounting for 15.14%, ranking second.</p><p>- Exports to the EU (excluding the UK) totaled USD 9.73 billion, accounting for 23.78%, ranking first, with Germany, the Netherlands, Belgium, Italy, and Spain being the top five EU markets for Chinese APIs.</p><p>Looking at the reverse side, in 2023, the EU’s API import value was USD 82.1 billion, with a compound annual growth rate of 15% over the past five years. The import sources were mainly concentrated in Switzerland, China, and the U.S., with these three countries accounting for 73% of the EU’s imports.</p><p>China’s Competitive Advantages in API Exports to the EU:</p><p>China holds significant advantages in the export of bulk APIs, where it has become the world’s largest exporter. China’s strengths include an abundance of production resources, a well-developed industrial workforce, and relatively low comprehensive costs, which secure its solid market position. However, the ongoing trend of reshoring APIs in regions such as the U.S., Europe, Japan, and India may pose short-term challenges in terms of “limited-scale substitution.”</p><p>For instance, India’s pharmaceutical industry has moved beyond importing penicillin industrial salt from China and is exploring the development of upstream fermentation processes. Although India’s fermentation technology lags behind China by around 7 to 8 years, it has already contributed to a decline in China’s export prices for penicillin industrial salt, 6-APA, and amoxicillin in 2024.</p><p>Key API Categories with High Sales Performance:</p><p>In the bulk and specialty API segments, products that perform well are those on which Europe, the U.S., Japan, and India heavily depend. These include antibiotics, vitamins, analgesics, antidiabetic drugs, cardiovascular drugs, anticancer drugs, antiviral drugs, and digestive system drugs. According to data from QYOBO, 37% of antibiotic APIs and 28% of oncology APIs are produced outside the EU. Diabetes and hypertension medications also heavily rely on China’s supply. However, as the EU pushes for supply chain diversification, these APIs may face increased competition from suppliers in the EU, India, and Southeast Asia.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/940/0*KKRtPzVSMu_jR2TI" /></figure><p>Intensifying Competition in Specialty APIs:</p><p>Specialty APIs are increasingly becoming a “focal point” of competition between Chinese and Indian companies in the EU market. In 2023, the EU issued 6,857 valid CEP (Certification of Suitability of Monographs of the European Pharmacopoeia) certificates for chemical APIs. The top five countries receiving these certifications were India, China, Italy, Germany, and Spain. The latter three are significant competitors within the EU for API production, in addition to India. The CEP certificate serves as a “passport” for access to the EU market. Since 2024, many Chinese companies have obtained these certificates, enabling their APIs to enter the EU market.</p><p>Historically, India has dominated the specialty API market in Europe and the U.S., while China has primarily focused on the Asian market. In the future, for China to break out of the “intense internal competition and transformation dilemma,” one direction is to seize opportunities presented by the patent cliff, with a focus on expanding the generic drug and specialty API market in Europe and the U.S.</p><p>Patent APIs:</p><p>The patent API market is largely dominated by the U.S. and Switzerland, home to powerful pharmaceutical companies such as Roche and Novartis. These companies play a pivotal role in the global pharmaceutical market, driving the development of upstream and downstream industrial chains, including API production and export.</p><p>Patent APIs have traditionally been dominated by large multinational pharmaceutical companies and a few leading Contract Development and Manufacturing Organizations (CDMOs). With the rise of China’s CXO (Contract eXternal Organizations) sector in the global pharmaceutical supply chain, China has gained a foothold in the high-value-added production of patent APIs. Additionally, China’s innovative drugs are rapidly entering overseas markets, including the EU, a trend expected to boost patent API exports as well.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=4d4c3bdd0c38" width="1" height="1" alt="">]]></content:encoded>
        </item>
    </channel>
</rss>